Matching articles for "corticosteroids"
Issue 1760 · August 3, 2026
Sibeprenlimab (Voyxact) for Primary Immunoglobulin A Nephropathy

Sibeprenlimab ( Voyxact – Otsuka), a subcutaneously injected cytokine A proliferation-inducing ligand (APRIL) blocker, has been granted accelerated approval by the FDA to reduce proteinuria in adults with…

Med Lett Drugs Ther. 2026 Aug 3; 68(1760):126-7 doi:10.58347/tml.2026.1760d
Sibeprenlimab ( Voyxact – Otsuka), a subcutaneously injected cytokine A proliferation-inducing ligand (APRIL) blocker, has been granted accelerated approval by the FDA to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN; also called Berger's disease) who are at risk for disease progression. Sibeprenlimab is the first APRIL blocker to be approved in the US. Atacicept (Trutakna) , a B-lymphocyte stimulator and APRIL blocker, was recently granted accelerated FDA approval for the same indication; it will be reviewed in a future issue.
Issue 1754 · May 11, 2026
Nipocalimab (Imaavy) for Myasthenia Gravis (online only)

The FDA has approved the neonatal Fc receptor (FcRn) blocker nipocalimab ( Imaavy – Janssen) for IV treatment of generalized myasthenia gravis (gMG) in patients ≥12 years old with anti-acetylcholine…

Med Lett Drugs Ther. 2026 May 11; 68(1754):e81-3 doi:10.58347/tml.2026.1754g
The FDA has approved the neonatal Fc receptor (FcRn) blocker nipocalimab ( Imaavy – Janssen) for IV treatment of generalized myasthenia gravis (gMG) in patients ≥12 years old with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. The FcRn blocker rozanolixizumab (Rystiggo) was approved earlier for the same indication.
Issue 1749 · March 2, 2026
Drugs for Atopic Dermatitis

Atopic dermatitis (AD), also known as eczema, is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and…

Med Lett Drugs Ther. 2026 Mar 2; 68(1749):33-40 doi:10.58347/tml.2026.1749a
Atopic dermatitis (AD), also known as eczema, is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into or first appearing in adulthood or even old age. Guidelines for the treatment of AD have recently been updated.
Issue 1740 · October 27, 2025
Deuruxolitinib (Leqselvi) for Severe Alopecia Areata

The FDA has approved the oral Janus kinase (JAK) inhibitor deuruxolitinib ( Leqselvi – Sun) for treatment of severe alopecia areata in adults. Two other oral JAK inhibitors are approved for treatment of…

Med Lett Drugs Ther. 2025 Oct 27; 67(1740):174-6 doi:10.58347/tml.2025.1740b
The FDA has approved the oral Janus kinase (JAK) inhibitor deuruxolitinib ( Leqselvi – Sun) for treatment of severe alopecia areata in adults. Two other oral JAK inhibitors are approved for treatment of severe alopecia areata: baricitinib (Olumiant) is approved for use in adults, and ritlecitinib (Litfulo) is approved for use in patients ≥12 years old.
Issue 1739 · October 13, 2025
Delgocitinib Cream (Anzupgo) for Chronic Hand Eczema

The FDA has approved a 2% cream formulation of delgocitinib ( Anzupgo – Leo), a Janus kinase (JAK) inhibitor, for treatment of moderate to severe chronic hand eczema (dermatitis) in adults who had an…

Med Lett Drugs Ther. 2025 Oct 13; 67(1739):163-5 doi:10.58347/tml.2025.1739b
The FDA has approved a 2% cream formulation of delgocitinib ( Anzupgo – Leo), a Janus kinase (JAK) inhibitor, for treatment of moderate to severe chronic hand eczema (dermatitis) in adults who had an inadequate response to or are unable to use topical corticosteroids. Delgocitinib is the first drug to be approved in the US for this indication. Ruxolitinib, another JAK inhibitor, is available in a 1.5% cream formulation (Opzelura) for treatment of mild to moderate atopic dermatitis in patients ≥2 years old.
Issue 1725 · March 31, 2025 Free
Treatment of Allergic Rhinitis and Allergic Conjunctivitis

Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).

Med Lett Drugs Ther. 2025 Mar 31; 67(1725):49-56 doi:10.58347/tml.2025.1725a
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Issue 1724 · March 17, 2025
Guselkumab (Tremfya) for Ulcerative Colitis

The interleukin (IL)-23 antagonist guselkumab ( Tremfya – Janssen Biotech) has now been approved by the FDA for treatment of moderately to severely active ulcerative colitis (UC) in adults; it was approved…

Med Lett Drugs Ther. 2025 Mar 17; 67(1724):46-8 doi:10.58347/tml.2025.1724d
The interleukin (IL)-23 antagonist guselkumab ( Tremfya – Janssen Biotech) has now been approved by the FDA for treatment of moderately to severely active ulcerative colitis (UC) in adults; it was approved earlier for treatment of plaque psoriasis and psoriatic arthritis. Guselkumab is the third IL-23 antagonist to be approved in the US for treatment of UC; risankizumab (Skyrizi) and mirikizumab (Omvoh) were approved earlier.
Issue 1722 · February 17, 2025
Nemolizumab (Nemluvio) for Atopic Dermatitis

Nemolizumab ( Nemluvio – Galderma), a subcutaneously injected interleukin-31 (IL-31) receptor antagonist, has been approved by the FDA for use in combination with topical corticosteroids and/or calcineurin…

Med Lett Drugs Ther. 2025 Feb 17; 67(1722):25-7 doi:10.58347/tml.2025.1722a
Nemolizumab ( Nemluvio – Galderma), a subcutaneously injected interleukin-31 (IL-31) receptor antagonist, has been approved by the FDA for use in combination with topical corticosteroids and/or calcineurin inhibitors for treatment of moderate to severe atopic dermatitis in patients ≥12 years old whose disease is not adequately controlled with topical prescription drugs. It is the first IL-31 receptor antagonist to be approved in the US for this indication. Nemolizumab was approved earlier for treatment of prurigo nodularis in adults.
Issue 1718 · December 23, 2024
Givinostat (Duvyzat) for Duchenne Muscular Dystrophy

Givinostat ( Duvyzat – Italfarmaco), an oral histone deacetylase inhibitor, has been approved by the FDA for treatment of patients ≥6 years old with Duchenne muscular dystrophy (DMD), regardless of the…

Med Lett Drugs Ther. 2024 Dec 23; 66(1718):204-5 doi:10.58347/tml.2024.1718c
Givinostat ( Duvyzat – Italfarmaco), an oral histone deacetylase inhibitor, has been approved by the FDA for treatment of patients ≥6 years old with Duchenne muscular dystrophy (DMD), regardless of the DMD-causing mutation. It is the first nonsteroidal drug to be approved for this indication. The oral corticosteroids deflazacort (Emflaza) and vamorolone (Agamree) are also approved for treatment of patients with all genetic variants of DMD.
Issue 1716 · November 25, 2024
Drugs for Asthma

The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations in the emergency department is not discussed here.

Med Lett Drugs Ther. 2024 Nov 25; 66(1716):185-92 doi:10.58347/tml.2024.1716a
The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations in the emergency department is not discussed here.
Issue 1715 · November 11, 2024
Axatilimab (Niktimvo) for Chronic Graft-Versus-Host Disease (online only)

Axatilimab-csfr ( Niktimvo – Incyte), a colony stimulating factor-1 receptor-blocking antibody, has been approved by the FDA for intravenous treatment of chronic graft-versus-host disease (cGVHD) after…

Med Lett Drugs Ther. 2024 Nov 11; 66(1715):e184-5 doi:10.58347/tml.2024.1715e
Axatilimab-csfr ( Niktimvo – Incyte), a colony stimulating factor-1 receptor-blocking antibody, has been approved by the FDA for intravenous treatment of chronic graft-versus-host disease (cGVHD) after failure of at least 2 lines of systemic therapy in patients weighing ≥40 kg. Corticosteroids are generally the first-line treatment for cGVHD. The oral kinase inhibitors ibrutinib (Imbruvica) , ruxolitinib (Jakafi) , and belumosudil (Rezurock) are also approved for treatment of cGVHD. Extracorporeal photopheresis has been used off-label.
Issue 1715 · November 11, 2024
Risankizumab (Skyrizi) for Ulcerative Colitis

The injectable interleukin (IL)-23 antagonist risankizumab-rzza ( Skyrizi – Abbvie), previously approved by the FDA for treatment of Crohn's disease (CD), has now been approved for treatment of moderately to…

Med Lett Drugs Ther. 2024 Nov 11; 66(1715):182-4 doi:10.58347/tml.2024.1715d
The injectable interleukin (IL)-23 antagonist risankizumab-rzza ( Skyrizi – Abbvie), previously approved by the FDA for treatment of Crohn's disease (CD), has now been approved for treatment of moderately to severely active ulcerative colitis (UC) in adults. Risankizumab is the first IL-23 antagonist to be approved for treatment of both CD and UC. It is also approved for treatment of plaque psoriasis and psoriatic arthritis.
Issue 1712 · September 30, 2024
Drugs for Plaque Psoriasis

Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with…

Med Lett Drugs Ther. 2024 Sep 30; 66(1712):153-60 doi:10.58347/tml.2024.1712a
Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with topical therapy, phototherapy, and systemic drugs have recently been published.
Issue 1711 · September 16, 2024
Roflumilast Cream (Zoryve) for Atopic Dermatitis

The FDA has approved a 0.15% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast ( Zoryve – Arcutis) for topical treatment of mild to moderate atopic dermatitis (AD) in patients ≥6…

Med Lett Drugs Ther. 2024 Sep 16; 66(1711):150-1 doi:10.58347/tml.2024.1711b
The FDA has approved a 0.15% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast ( Zoryve – Arcutis) for topical treatment of mild to moderate atopic dermatitis (AD) in patients ≥6 years old. Roflumilast is the second PDE4 inhibitor to be approved in the US for treatment of AD; crisaborole (Eucrisa) , which can be used in patients ≥3 months old, was the first. Roflumilast is available as Zoryve in a 0.3% cream for treatment of plaque psoriasis and a 0.3% foam for treatment of seborrheic dermatitis. It is also available in an oral formulation (Daliresp) for treatment of chronic obstructive pulmonary disease.
Issue 1702 · May 13, 2024
Sarilumab (Kevzara) for Polymyalgia Rheumatica

The FDA has approved the interleukin (IL)-6 inhibitor sarilumab ( Kevzara – Sanofi/Regeneron) for treatment of polymyalgia rheumatica (PMR) in adults who had an inadequate response to corticosteroids or…

Med Lett Drugs Ther. 2024 May 13; 66(1702):77-8 doi:10.58347/tml.2024.1702c
The FDA has approved the interleukin (IL)-6 inhibitor sarilumab ( Kevzara – Sanofi/Regeneron) for treatment of polymyalgia rheumatica (PMR) in adults who had an inadequate response to corticosteroids or cannot tolerate a corticosteroid taper. Sarilumab is the first biologic drug to be approved for treatment of PMR; it was previously approved for treatment of rheumatoid arthritis.
Issue 1700 · April 15, 2024
Roflumilast Foam (Zoryve) for Seborrheic Dermatitis

The FDA has approved a 0.3% foam formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast ( Zoryve – Arcutis) for topical treatment of seborrheic dermatitis in patients ≥9 years old. Roflumilast…

Med Lett Drugs Ther. 2024 Apr 15; 66(1700):57-9 doi:10.58347/tml.2024.1700a
The FDA has approved a 0.3% foam formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast ( Zoryve – Arcutis) for topical treatment of seborrheic dermatitis in patients ≥9 years old. Roflumilast is the first PDE4 inhibitor to be approved in the US for this indication. It is also available in a 0.3% cream formulation (Zoryve) for treatment of plaque psoriasis and in an oral formulation ( Dalires p, and generics) for treatment of chronic obstructive pulmonary disease. A 0.15% cream formulation for treatment of atopic dermatitis in patients ≥6 years old will be reviewed by the FDA in July.
Issue 1688 · October 30, 2023
Drugs for Gout

Drugs for gout are used to reduce the pain and inflammation of acute flares, decrease the frequency of exacerbations, and lower serum urate levels to prevent recurrent flares, development of tophi, and joint…

Med Lett Drugs Ther. 2023 Oct 30; 65(1688):169-75 doi:10.58347/tml.2023.1688a
Drugs for gout are used to reduce the pain and inflammation of acute flares, decrease the frequency of exacerbations, and lower serum urate levels to prevent recurrent flares, development of tophi, and joint damage.
Issue 1686 · October 2, 2023
Delandistrogene Moxeparvovec (Elevidys) for Duchenne Muscular Dystrophy

Delandistrogene moxeparvovec-rokl ( Elevidys – Sarepta), an adeno-associated virus (AAV) vector-based gene therapy, has received accelerated approval from the FDA for treatment of ambulatory children 4-5…

Med Lett Drugs Ther. 2023 Oct 2; 65(1686):159-60 doi:10.58347/tml.2023.1686d
Delandistrogene moxeparvovec-rokl ( Elevidys – Sarepta), an adeno-associated virus (AAV) vector-based gene therapy, has received accelerated approval from the FDA for treatment of ambulatory children 4-5 years old with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene. It is the first gene therapy to be approved in the US for treatment of DMD. Accelerated approval was based on expression of microdystrophin in skeletal muscle, a surrogate endpoint.
Issue 1682 · August 7, 2023 Free
In Brief: Tafasitamab (Monjuvi) for Diffuse Large B-Cell Lymphoma (online only)

Tafasitamab-cxix ( Monjuvi – Morphosys), a CD19-directed cytolytic antibody, has received accelerated approval from the FDA for use in combination with lenalidomide (Revlimid) for treatment of relapsed or…

Med Lett Drugs Ther. 2023 Aug 7; 65(1682):e133 doi:10.58347/tml.2023.1682d
Tafasitamab-cxix ( Monjuvi – Morphosys), a CD19-directed cytolytic antibody, has received accelerated approval from the FDA for use in combination with lenalidomide (Revlimid) for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from low grade lymphoma, in adults who are not eligible for autologous stem cell transplant. Accelerated approval was based on overall response rates.
Issue 1680 · July 10, 2023
Drugs for Inflammatory Bowel Disease

Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have…

Med Lett Drugs Ther. 2023 Jul 10; 65(1680):105-12 doi:10.58347/tml.2023.1680a
Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have been updated in recent years
Issue 1680 · July 10, 2023
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)

View the Table: Some Drugs for Inflammatory Bowel Disease

Med Lett Drugs Ther. 2023 Jul 10; 65(1680):e115-9 doi:10.58347/tml.2023.1680d
View the Table: Some Drugs for Inflammatory Bowel Disease
Issue 1680 · July 10, 2023
Table: Safety of Drugs for IBD in Pregnancy (online only)

View the Table: Safety of Drugs for IBD in Pregnancy

Med Lett Drugs Ther. 2023 Jul 10; 65(1680):e113 doi:10.58347/tml.2023.1680b
View the Table: Safety of Drugs for IBD in Pregnancy
Issue 1673 · April 3, 2023
Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)

The subcutaneously injected interleukin-13 (IL-13) antagonist tralokinumab-ldrm ( Adbry – Leo) and the oral Janus kinase (JAK) inhibitors abrocitinib ( Cibinqo – Pfizer) and upadacitinib ( Rinvoq –…

Med Lett Drugs Ther. 2023 Apr 3; 65(1673):51-5 doi:10.58347/tml.2023.1673b
The subcutaneously injected interleukin-13 (IL-13) antagonist tralokinumab-ldrm ( Adbry – Leo) and the oral Janus kinase (JAK) inhibitors abrocitinib ( Cibinqo – Pfizer) and upadacitinib ( Rinvoq – Abbvie) have been approved by the FDA for treatment of moderate to severe atopic dermatitis.
Issue 1668 · January 23, 2023
Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis

The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H 1 -antihistamine olopatadine hydrochloride ( Patanase , and generics) and the corticosteroid mometasone furoate (…

Med Lett Drugs Ther. 2023 Jan 23; 65(1668):12-4 doi:10.58347/tml.2023.1668c
The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H 1 -antihistamine olopatadine hydrochloride ( Patanase , and generics) and the corticosteroid mometasone furoate ( Nasonex 24 HR Allergy , and generics), for treatment of seasonal allergic rhinitis symptoms in persons ≥12 years old. Ryaltris is the second intranasal antihistamine/corticosteroid combination to be approved for this indication; azelastine 0.1%/fluticasone propionate ( Dymista , and generics), which is approved for use in persons ≥6 years old, was the first. Both products are available only by prescription.
Issue 1668 · January 23, 2023
Topical Roflumilast (Zoryve) for Plaque Psoriasis

The FDA has approved a 0.3% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast ( Zoryve – Arcutis) for topical treatment of plaque psoriasis in patients ≥12 years old. Roflumilast is…

Med Lett Drugs Ther. 2023 Jan 23; 65(1668):10-2 doi:10.58347/tml.2023.1668b
The FDA has approved a 0.3% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast ( Zoryve – Arcutis) for topical treatment of plaque psoriasis in patients ≥12 years old. Roflumilast is the first topical PDE4 inhibitor to be approved by the FDA for this indication; crisaborole (Eucrisa) , another topical PDE4 inhibitor, is approved for treatment of atopic dermatitis. Oral roflumilast (Daliresp) is approved for treatment of chronic obstructive pulmonary disease.
Issue 1666 · December 26, 2022
Risankizumab (Skyrizi) - An IL-23 Antagonist for Crohn's Disease

The injectable interleukin (IL)-23 antagonist risankizumab-rzaa ( Skyrizi – Abbvie) has been approved by the FDA for treatment of moderately to severely active Crohn's disease (CD) in adults. Risankizumab…

Med Lett Drugs Ther. 2022 Dec 26; 64(1666):205-7
The injectable interleukin (IL)-23 antagonist risankizumab-rzaa ( Skyrizi – Abbvie) has been approved by the FDA for treatment of moderately to severely active Crohn's disease (CD) in adults. Risankizumab was approved earlier for treatment of plaque psoriasis and psoriatic arthritis.
Issue 1665 · December 12, 2022 Free
An EUA for Anakinra (Kineret) for COVID-19 (online only)

The recombinant interleukin-1 (IL-1) receptor antagonist anakinra ( Kineret – Sobi) has been granted an FDA Emergency Use Authorization (EUA) for treatment of hospitalized adults with confirmed COVID-19…

Med Lett Drugs Ther. 2022 Dec 12; 64(1665):e203-4
The recombinant interleukin-1 (IL-1) receptor antagonist anakinra ( Kineret – Sobi) has been granted an FDA Emergency Use Authorization (EUA) for treatment of hospitalized adults with confirmed COVID-19 pneumonia who require low- or high-flow supplemental oxygen, are at risk of progressing to severe respiratory failure, and are likely to have elevated plasma levels of soluble urokinase plasminogen activator receptor (suPAR). Anakinra has been available in the US for years; it is FDA-approved for multiple indications, including rheumatoid arthritis. Assays for suPAR are not commercially available in the US.
Issue 1660 · October 3, 2022
Ruxolitinib Cream (Opzelura) for Nonsegmental Vitiligo

The 1.5% cream formulation of the Janus kinase (JAK) inhibitor ruxolitinib ( Opzelura – Incyte) has been approved by the FDA for topical treatment of nonsegmental vitiligo (NSV) in patients ≥12 years old.…

Med Lett Drugs Ther. 2022 Oct 3; 64(1660):158-9
The 1.5% cream formulation of the Janus kinase (JAK) inhibitor ruxolitinib ( Opzelura – Incyte) has been approved by the FDA for topical treatment of nonsegmental vitiligo (NSV) in patients ≥12 years old. Opzelura is the first product to be approved by the FDA for this indication. It was previously approved for treatment of atopic dermatitis.
Issue 1658 · September 5, 2022
Baricitinib (Olumiant) for Severe Alopecia Areata

The oral Janus kinase (JAK) inhibitor baricitinib ( Olumiant – Lilly), which was previously approved by the FDA for treatment of moderately to severely active rheumatoid arthritis and treatment of COVID-19…

Med Lett Drugs Ther. 2022 Sep 5; 64(1658):139-41
The oral Janus kinase (JAK) inhibitor baricitinib ( Olumiant – Lilly), which was previously approved by the FDA for treatment of moderately to severely active rheumatoid arthritis and treatment of COVID-19 in certain hospitalized adults, has now been approved for treatment of severe alopecia areata in adults. Baricitinib is the first systemic treatment to be approved in the US for this indication.
Issue 1658 · September 5, 2022
Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis

The FDA has approved the oral Janus kinase (JAK) inhibitor upadacitinib ( Rinvoq – Abbvie) for treatment of moderately to severely active ulcerative colitis in adults who have had an inadequate response to…

Med Lett Drugs Ther. 2022 Sep 5; 64(1658):142-4
The FDA has approved the oral Janus kinase (JAK) inhibitor upadacitinib ( Rinvoq – Abbvie) for treatment of moderately to severely active ulcerative colitis in adults who have had an inadequate response to or cannot tolerate one or more tumor necrosis factor (TNF) inhibitors. Upadacitinib is the second JAK inhibitor to be approved for this indication; tofacitinib (Xeljanz) was the first. Upadacitinib is also approved for treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ankylosing spondylitis.
Issue 1650 · May 16, 2022
Delayed-Release Budesonide (Tarpeyo) for Primary Immunoglobulin A Nephropathy

The FDA has approved Tarpeyo (Calliditas), a delayed-release capsule formulation of the corticosteroid budesonide, to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN; also called…

Med Lett Drugs Ther. 2022 May 16; 64(1650):76-7
The FDA has approved Tarpeyo (Calliditas), a delayed-release capsule formulation of the corticosteroid budesonide, to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN; also called Berger's disease) who are at risk of rapid disease progression. It is the fi rst drug to be approved in the US for this indication. Oral formulations of budesonide have been available for years for treatment of inflammatory bowel disease.
Issue 1648 · April 18, 2022
A Drug-Eluting Contact Lens for Allergic Conjunctivitis

The FDA has approved Acuvue Theravision with Ketotifen (Johnson & Johnson Vision Care), a daily-wear, disposable, vision-correcting soft contact lens that releases the H 1 -antihistamine ketotifen, for…

Med Lett Drugs Ther. 2022 Apr 18; 64(1648):60-1
The FDA has approved Acuvue Theravision with Ketotifen (Johnson & Johnson Vision Care), a daily-wear, disposable, vision-correcting soft contact lens that releases the H 1 -antihistamine ketotifen, for prevention of ocular itch due to allergic conjunctivitis in contact lens users. This is the first approval for a drug-eluting contact lens. Ketotifen eye drops ( Alaway, Zaditor, and others) are available over the counter.
Issue 1648 · April 18, 2022
Efgartigimod alfa (Vyvgart) for Myasthenia Gravis

Efgartigimod alfa-fcab ( Vyvgart – Argenx), a first-in-class neonatal Fc receptor (FcRn) antagonist, has been approved by the FDA for IV treatment of generalized myasthenia gravis in adults who are…

Med Lett Drugs Ther. 2022 Apr 18; 64(1648):62-3
Efgartigimod alfa-fcab ( Vyvgart – Argenx), a first-in-class neonatal Fc receptor (FcRn) antagonist, has been approved by the FDA for IV treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive. The IV complement inhibitor eculizumab (Soliris) was approved for the same indication in 2017.
Issue 1645 · March 7, 2022
Nonopioid Drugs for Pain

Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive…

Med Lett Drugs Ther. 2022 Mar 7; 64(1645):33-40
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive nonpharmacologic treatments, including physical and psychological therapies, have been shown to improve pain and function in patients with some common chronic pain conditions and are unlikely to cause serious harms. A multimodal approach to analgesic therapy can increase pain control while reducing opioid use and adverse effects.
Issue 1642 · January 24, 2022
Ruxolitinib (Opzelura) for Atopic Dermatitis

The FDA has approved a 1.5% topical cream formulation of the Janus kinase (JAK) inhibitor ruxolitinib ( Opzelura – Incyte) for short-term, non-continuous chronic treatment of mild to moderate atopic…

Med Lett Drugs Ther. 2022 Jan 24; 64(1642):12-3
The FDA has approved a 1.5% topical cream formulation of the Janus kinase (JAK) inhibitor ruxolitinib ( Opzelura – Incyte) for short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients ≥12 years old whose disease has not been adequately controlled with other topical prescription drugs. Ruxolitinib is the first JAK inhibitor to be approved for topical use and the first to be approved in the US for treatment of AD. An oral formulation of ruxolitinib (Jakafi) is approved for treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.
Issue 1637 · November 15, 2021
Drugs for Rheumatoid Arthritis

Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were…

Med Lett Drugs Ther. 2021 Nov 15; 63(1637):177-84
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Issue 1634 · September 23, 2021
Belimumab (Benlysta) for Lupus Nephritis (online only)

The B-lymphocyte stimulator (BLyS)-specific inhibitor belimumab ( Benlysta – GSK), which was approved earlier for treatment of active, autoantibody-positive, nonrenal, systemic lupus erythematosus (SLE), has…

Med Lett Drugs Ther. 2021 Sep 23; 63(1634):e3-4
The B-lymphocyte stimulator (BLyS)-specific inhibitor belimumab ( Benlysta – GSK), which was approved earlier for treatment of active, autoantibody-positive, nonrenal, systemic lupus erythematosus (SLE), has now been approved for use in addition to standard therapy for treatment of active lupus nephritis in adults. Belimumab is the first drug to be approved in the US for treatment of both SLE and lupus nephritis.
Issue 1633 · September 20, 2021
Anifrolumab (Saphnelo) for Systemic Lupus Erythematosus

The FDA has approved anifrolumab-fnia ( Saphnelo – AstraZeneca), a type I interferon receptor antagonist, for IV treatment of adults with moderate to severe systemic lupus erythematosus (SLE) who are…

Med Lett Drugs Ther. 2021 Sep 20; 63(1633):146-7
The FDA has approved anifrolumab-fnia ( Saphnelo – AstraZeneca), a type I interferon receptor antagonist, for IV treatment of adults with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard treatment. Anifrolumab has not been studied in patients with severe active lupus nephritis or severe active CNS lupus. It is the first type I interferon receptor antagonist to become available in the US.
Issue 1633 · September 20, 2021
Ozanimod (Zeposia) for Ulcerative Colitis

The oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod ( Zeposia – Bristol Myers Squibb) has been approved by the FDA for treatment of adults with moderately to severely active ulcerative…

Med Lett Drugs Ther. 2021 Sep 20; 63(1633):147-51
The oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod ( Zeposia – Bristol Myers Squibb) has been approved by the FDA for treatment of adults with moderately to severely active ulcerative colitis. It is the first S1P receptor modulator to be approved for treatment of ulcerative colitis. Ozanimod was approved in March 2020 for use in adults with relapsing forms of multiple sclerosis.
Issue 1631 · August 23, 2021
Voclosporin (Lupkynis) for Lupus Nephritis

Voclosporin ( Lupkynis – Aurinia), an oral calcineurin inhibitor, has been approved by the FDA for use in combination with the antimetabolite immunosuppressant mycophenolate mofetil ( Cellcept , and…

Med Lett Drugs Ther. 2021 Aug 23; 63(1631):134-6
Voclosporin ( Lupkynis – Aurinia), an oral calcineurin inhibitor, has been approved by the FDA for use in combination with the antimetabolite immunosuppressant mycophenolate mofetil ( Cellcept , and generics) and a corticosteroid for treatment of adults with active lupus nephritis. It is the first calcineurin inhibitor to be approved in the US for this indication. Tacrolimus ( Prograf , and others) and cyclosporine ( Neoral , and others), the other available systemic calcineurin inhibitors, are approved for prophylaxis of organ rejection in transplant patients.
Issue 1629 · July 26, 2021 Free
An EUA for Tocilizumab (Actemra) for COVID-19

The interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) has received an Emergency Use Authorization (EUA) from the FDA for IV treatment of COVID-19 in hospitalized patients ≥2 years…

Med Lett Drugs Ther. 2021 Jul 26; 63(1629):113-4
The interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) has received an Emergency Use Authorization (EUA) from the FDA for IV treatment of COVID-19 in hospitalized patients ≥2 years old who are receiving a systemic corticosteroid and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Tocilizumab has been approved by the FDA for various indications, including rheumatoid arthritis and juvenile idiopathic arthritis.
Issue 1625 · May 31, 2021
Teprotumumab (Tepezza) for Thyroid Eye Disease

Teprotumumab-trbw ( Tepezza - Horizon), an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, has been approved by the FDA for IV treatment of thyroid eye disease. It is the first drug to be approved in…

Med Lett Drugs Ther. 2021 May 31; 63(1625):87-8
Teprotumumab-trbw ( Tepezza - Horizon), an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, has been approved by the FDA for IV treatment of thyroid eye disease. It is the first drug to be approved in the US for this indication.
Issue 1622 · April 19, 2021
Drugs for Allergic Rhinitis and Allergic Conjunctivitis

The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).

Med Lett Drugs Ther. 2021 Apr 19; 63(1622):57-64
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Issue 1600 · June 15, 2020
Drugs for Atopic Dermatitis

Atopic dermatitis (AD; also known as eczema) is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and…

Med Lett Drugs Ther. 2020 Jun 15; 62(1600):89-96
Atopic dermatitis (AD; also known as eczema) is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into (or first appearing in) adulthood or even old age.
Issue 1599 · June 1, 2020
Cetirizine Ophthalmic Solution (Zerviate) for Allergic Conjunctivitis

A 0.24% ophthalmic solution of the second-generation H 1 -antihistamine cetirizine ( Zerviate – Eyevance) is now available by prescription for treatment of ocular itching associated with allergic…

Med Lett Drugs Ther. 2020 Jun 1; 62(1599):81-3
A 0.24% ophthalmic solution of the second-generation H 1 -antihistamine cetirizine ( Zerviate – Eyevance) is now available by prescription for treatment of ocular itching associated with allergic conjunctivitis in patients ≥2 years old. Oral cetirizine ( Zyrtec , and others), which is used for treatment of allergic conjunctivitis and rhinitis, has been available over the counter (OTC) for years.
Issue 1597 · May 4, 2020 Free
In Brief: Neuropsychiatric Events with Montelukast

The FDA is requiring stronger warnings in the labeling of the leukotriene receptor antagonist montelukast ( Singulair , and generics) about the risk of suicidal behavior and other serious neuropsychiatric…

Med Lett Drugs Ther. 2020 May 4; 62(1597):65
The FDA is requiring stronger warnings in the labeling of the leukotriene receptor antagonist montelukast ( Singulair , and generics) about the risk of suicidal behavior and other serious neuropsychiatric events associated with its use.
Issue 1596 · April 20, 2020
Drugs for Osteoarthritis

Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Nonpharmacologic approaches including weight management, exercise, tai chi, physical…

Med Lett Drugs Ther. 2020 Apr 20; 62(1596):57-62
Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Nonpharmacologic approaches including weight management, exercise, tai chi, physical therapy, assistive devices, and total joint arthroplasty can also be used. The American College of Rheumatology (ACR) has published new guidelines for the management of osteoarthritis of the hip, hand, and knee.
Issue 1595 · April 6, 2020 Free
Some Drugs for COVID-19

The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in…

Med Lett Drugs Ther. 2020 Apr 6; 62(1595):49-50
The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in treating it. Definitive answers are lacking, but some recommendations can be made. For additional information on specific drugs, see our table Some Drugs Being Considered for Treatment of COVID-19.
Issue 1595 · April 6, 2020 Free
Table: Treatments Considered for COVID-19 (Archived) (online only)

View the Table: Treatments Considered for COVID-19

Med Lett Drugs Ther. 2020 Apr 6; 62(1595):e1-289
View the Table: Treatments Considered for COVID-19
Issue 1919 · April 6, 2020 Free
Some Drugs for COVID-19

The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in…

Med Lett Drugs Ther. 2020 Apr 6; 62(1919):1 doi:10.58347/tml.2020.1919a
The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in treating it. Definitive answers are lacking, but some recommendations can be made. For additional information on specific drugs, see our table Some Drugs Being Considered for Treatment of COVID-19.
Issue 1589 · January 13, 2020
Corticosteroids in Community-Acquired Pneumonia

Recently updated guidelines from the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) address the use of corticosteroids as an adjunct to antimicrobials for treatment of…

Med Lett Drugs Ther. 2020 Jan 13; 62(1589):7-8
Recently updated guidelines from the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) address the use of corticosteroids as an adjunct to antimicrobials for treatment of community-acquired pneumonia (CAP).
Issue 1588 · December 30, 2019
Drugs for Psoriatic Arthritis

Psoriatic arthritis is a chronic inflammatory arthropathy associated with psoriasis. A recent review found that about 20% of patients with psoriasis have psoriatic arthritis. Updated guidelines for treatment…

Med Lett Drugs Ther. 2019 Dec 30; 61(1588):203-10
Psoriatic arthritis is a chronic inflammatory arthropathy associated with psoriasis. A recent review found that about 20% of patients with psoriasis have psoriatic arthritis. Updated guidelines for treatment of psoriatic arthritis have recently been published.
Issue 1573 · June 3, 2019
Risankizumab (Skyrizi) for Psoriasis

The FDA has approved the interleukin (IL)-23 antagonist risankizumab-rzaa ( Skyrizi – Abbvie) for treatment of moderate to severe plaque psoriasis in adults. Risankizumab is the third IL-23 antagonist to be…

Med Lett Drugs Ther. 2019 Jun 3; 61(1573):81-3
The FDA has approved the interleukin (IL)-23 antagonist risankizumab-rzaa ( Skyrizi – Abbvie) for treatment of moderate to severe plaque psoriasis in adults. Risankizumab is the third IL-23 antagonist to be approved for this indication; guselkumab (Tremfya) and tildrakizumab (Ilumya) were approved earlier.
Issue 1567 · March 11, 2019
Drugs for Gout

Drugs for gout reduce the pain and inflammation of acute flares and lower serum urate levels in order to prevent recurrent flares, development of tophi, and joint damage.

Med Lett Drugs Ther. 2019 Mar 11; 61(1567):33-7
Drugs for gout reduce the pain and inflammation of acute flares and lower serum urate levels in order to prevent recurrent flares, development of tophi, and joint damage.
Issue 1563 · January 14, 2019
Tildrakizumab (Ilumya) - Another IL-23 Antagonist for Psoriasis

Tildrakizumab-asmn ( Ilumya – Sun), an interleukin (IL)-23 antagonist, has been approved by the FDA for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or…

Med Lett Drugs Ther. 2019 Jan 14; 61(1563):4-6
Tildrakizumab-asmn ( Ilumya – Sun), an interleukin (IL)-23 antagonist, has been approved by the FDA for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tildrakizumab is the second selective IL-23 antagonist to be approved for this indication; guselkumab (Tremfya) was the first.
Issue 1563 · January 14, 2019
Dupilumab (Dupixent) for Asthma

The FDA has approved the subcutaneously injected monoclonal antibody dupilumab ( Dupixent – Sanofi/Regeneron) for add-on maintenance treatment of patients ≥12 years old with moderate to severe asthma with…

Med Lett Drugs Ther. 2019 Jan 14; 61(1563):6-8
The FDA has approved the subcutaneously injected monoclonal antibody dupilumab ( Dupixent – Sanofi/Regeneron) for add-on maintenance treatment of patients ≥12 years old with moderate to severe asthma with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Dupilumab was approved earlier to treat adults with moderate to severe atopic dermatitis inadequately controlled with topical therapies.
Issue 1562 · December 17, 2018 Free
Drugs for Cough

Acute cough (<3 weeks in duration) generally does not require pharmacologic treatment, especially in children. Suppression of productive cough may be harmful. Management of patients with cough should include…

Med Lett Drugs Ther. 2018 Dec 17; 60(1562):206-8
Acute cough (<3 weeks in duration) generally does not require pharmacologic treatment, especially in children. Suppression of productive cough may be harmful. Management of patients with cough should include elimination of any precipitating factor (e.g., cigarette smoking) and treatment of any underlying cause such as upper airway cough syndrome, gastroesophageal reflux disease, asthma, or other pulmonary disease.
Issue 1554 · August 27, 2018
Two New Intra-Articular Injections for Knee Osteoarthritis

The FDA has approved a single-injection hyaluronic acid gel ( Durolane – Bioventus) and an extended-release (ER) formulation of the synthetic corticosteroid triamcinolone acetonide ( Zilretta – Flexion)…

Med Lett Drugs Ther. 2018 Aug 27; 60(1554):142-4
The FDA has approved a single-injection hyaluronic acid gel ( Durolane – Bioventus) and an extended-release (ER) formulation of the synthetic corticosteroid triamcinolone acetonide ( Zilretta – Flexion) for intra-articular (IA) treatment of osteoarthritic knee pain.
Issue 1552 · July 30, 2018
Drugs for Rheumatoid Arthritis

Disease-modifying antirheumatic drugs (DMARDs) are used for initial treatment of rheumatoid arthritis (RA) to achieve clinical remission and prevent irreversible joint damage (see Table 1). DMARDs generally do…

Med Lett Drugs Ther. 2018 Jul 30; 60(1552):123-8
Disease-modifying antirheumatic drugs (DMARDs) are used for initial treatment of rheumatoid arthritis (RA) to achieve clinical remission and prevent irreversible joint damage (see Table 1). DMARDs generally do not have an immediate analgesic effect, but over time they can control symptoms and have been shown to delay and possibly stop progression of the disease. Methotrexate ( Trexall , and others) is generally the drug of choice; it can be used for patients with low, moderate, or high disease activity. For mild disease, some clinicians prefer to start with hydroxychloroquine ( Plaquenil , and generics) and/or sulfasalazine ( Azulfidine , and others).
Issue 1551 · July 16, 2018
Baricitinib (Olumiant) for Rheumatoid Arthritis

The FDA has approved the Janus kinase (JAK) inhibitor baricitinib ( Olumiant – Lilly) for oral treatment of adults with moderately to severely active rheumatoid arthritis (RA) that has not responded…

Med Lett Drugs Ther. 2018 Jul 16; 60(1551):120-1
The FDA has approved the Janus kinase (JAK) inhibitor baricitinib ( Olumiant – Lilly) for oral treatment of adults with moderately to severely active rheumatoid arthritis (RA) that has not responded adequately to one or more tumor necrosis factor (TNF) inhibitors. Baricitinib is the second JAK inhibitor to be approved for treatment of RA; tofacitinib (Xeljanz, Xeljanz XR) was the first.
Issue 1551 · July 16, 2018
Axicabtagene Ciloleucel (Yescarta) for B-Cell Lymphoma (online only)

The FDA has approved axicabtagene ciloleucel ( Yescarta – Kite) for treatment of adults with relapsed or refractory CD19+ large B-cell lymphoma after ≥2 lines of systemic therapy. Yescarta is an…

Med Lett Drugs Ther. 2018 Jul 16; 60(1551):e122-3
The FDA has approved axicabtagene ciloleucel ( Yescarta – Kite) for treatment of adults with relapsed or refractory CD19+ large B-cell lymphoma after ≥2 lines of systemic therapy. Yescarta is an individualized cellular product prepared from the patient's own T cells, which are genetically modified to express chimeric antigen receptors (CAR) and then infused back into the patient. It is the second CAR T-cell immunotherapy to become available in the US. Tisagenlecleucel (Kymriah ), a CAR T-cell product previously approved for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in patients ≤25 years old, was recently also approved for relapsed or refractory CD19+ large B-cell lymphoma after ≥2 lines of systemic therapy.
Issue 1550 · July 2, 2018
Drugs for Inflammatory Bowel Disease

Management of both ulcerative colitis (UC) and Crohn's disease (CD) is based on disease severity. Disease location (proctitis, left-sided colitis, or extensive colitis) also plays a role in drug selection.…

Med Lett Drugs Ther. 2018 Jul 2; 60(1550):107-14
Management of both ulcerative colitis (UC) and Crohn's disease (CD) is based on disease severity. Disease location (proctitis, left-sided colitis, or extensive colitis) also plays a role in drug selection. Some drugs for induction and maintenance of remission of inflammatory bowel disease (IBD) are listed in Table 1.
Issue 1550 · July 2, 2018
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)

View Expanded Table: Some Drugs for Inflammatory Bowel Disease

Med Lett Drugs Ther. 2018 Jul 2; 60(1550):e117-22
View Expanded Table: Some Drugs for Inflammatory Bowel Disease
Issue 1550 · July 2, 2018
Table: Drugs for Ulcerative Colitis (online only)

View Table: Drugs for Ulcerative Colitis

Med Lett Drugs Ther. 2018 Jul 2; 60(1550):e114
View Table: Drugs for Ulcerative Colitis
Issue 1550 · July 2, 2018
Table: Drugs for Crohn's Disease (online only)

View Table: Drugs for Crohn's Disease

Med Lett Drugs Ther. 2018 Jul 2; 60(1550):e115
View Table: Drugs for Crohn's Disease
Issue 1550 · July 2, 2018
Table: Safety of Drugs for IBD in Pregnancy (online only)

View Table: Safety of Drugs for IBD in Pregnancy

Med Lett Drugs Ther. 2018 Jul 2; 60(1550):e116
View Table: Safety of Drugs for IBD in Pregnancy
Issue 1541 · February 26, 2018
Benralizumab (Fasenra) for Severe Eosinophilic Asthma

The FDA has approved benralizumab ( Fasenra – AstraZeneca), a humanized monoclonal antibody selective for the interleukin-5 (IL-5) receptor, for add-on maintenance treatment of severe asthma in patients…

Med Lett Drugs Ther. 2018 Feb 26; 60(1541):33-5
The FDA has approved benralizumab ( Fasenra – AstraZeneca), a humanized monoclonal antibody selective for the interleukin-5 (IL-5) receptor, for add-on maintenance treatment of severe asthma in patients ≥12 years old with an eosinophilic phenotype. Benralizumab is the third anti-IL-5 antibody to be approved for treatment of severe eosinophilic asthma; mepolizumab (Nucala) and reslizumab (Cinqair ), which target IL-5 itself, were approved earlier.
Issue 1540 · February 12, 2018
Nonopioid Drugs for Pain

Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. Use of opioids for pain will be reviewed in a future issue.

Med Lett Drugs Ther. 2018 Feb 12; 60(1540):24-32
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. Use of opioids for pain will be reviewed in a future issue.
Issue 1530 · September 25, 2017
Tocilizumab (Actemra) for Giant Cell Arteritis

The FDA has approved the interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) for subcutaneous (SC) treatment of giant cell arteritis in adults. It is the first drug to be approved in…

Med Lett Drugs Ther. 2017 Sep 25; 59(1530):161-2
The FDA has approved the interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) for subcutaneous (SC) treatment of giant cell arteritis in adults. It is the first drug to be approved in the US for this indication. Tocilizumab is also approved for treatment of rheumatoid arthritis, polyarticular or systemic juvenile idiopathic arthritis, and cytokine release syndrome.
Issue 1528 · August 28, 2017
Drugs for Asthma

The goal of asthma treatment is to control symptoms and prevent exacerbations. Management of acute exacerbations of asthma is not discussed here.

Med Lett Drugs Ther. 2017 Aug 28; 59(1528):139-46
The goal of asthma treatment is to control symptoms and prevent exacerbations. Management of acute exacerbations of asthma is not discussed here.
Issue 1525 · July 17, 2017
Brodalumab (Siliq) - Another IL-17A Antagonist for Psoriasis

The FDA has approved brodalumab ( Siliq – Valeant), an injectable human interleukin (IL)-17A receptor antagonist, for treatment of adults with moderate to severe plaque psoriasis who have failed to respond…

Med Lett Drugs Ther. 2017 Jul 17; 59(1525):118-9
The FDA has approved brodalumab ( Siliq – Valeant), an injectable human interleukin (IL)-17A receptor antagonist, for treatment of adults with moderate to severe plaque psoriasis who have failed to respond to other systemic therapies. Brodalumab is the third IL-17A antagonist to be approved in the US for this indication; secukinumab (Cosentyx) and ixekizumab (Taltz) were approved earlier.
Issue 1520 · May 8, 2017
Drugs for Allergic Disorders

Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma. H 1 -ANTIHISTAMINES — Oral – Oral second-generation…

Med Lett Drugs Ther. 2017 May 8; 59(1520):71-82
Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma. H 1 -ANTIHISTAMINES — Oral – Oral second-generation H 1 -antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis. They are less effective for nasal congestion.
Issue 1519 · April 24, 2017
Dupilumab (Dupixent) for Moderate to Severe Atopic Dermatitis

The FDA has approved dupilumab ( Dupixent – Sanofi/Regeneron), a subcutaneously-injected fully human monoclonal antibody, for treatment of adults with moderate to severe atopic dermatitis (eczema) that has…

Med Lett Drugs Ther. 2017 Apr 24; 59(1519):64-6
The FDA has approved dupilumab ( Dupixent – Sanofi/Regeneron), a subcutaneously-injected fully human monoclonal antibody, for treatment of adults with moderate to severe atopic dermatitis (eczema) that has not responded to topical therapies. It can be used with or without topical corticosteroids.
Issue 1519 · April 24, 2017
OTC Fluticasone Furoate Nasal Spray (Flonase Sensimist) for Allergic Rhinitis (online only)

The nasal spray formulation of the corticosteroid fluticasone furoate is now available over the counter (OTC) as Flonase Sensimist Allergy Relief (GSK) in the same strength as the prescription product…

Med Lett Drugs Ther. 2017 Apr 24; 59(1519):e70-1
The nasal spray formulation of the corticosteroid fluticasone furoate is now available over the counter (OTC) as Flonase Sensimist Allergy Relief (GSK) in the same strength as the prescription product (Veramyst) for treatment of seasonal or perennial allergic rhinitis. It is the fourth intranasal corticosteroid to become available OTC.
Issue 1515 · February 27, 2017
Crisaborole (Eucrisa) for Atopic Dermatitis

The FDA has approved crisaborole 2% ointment ( Eucrisa – Pfizer) for topical treatment of mild to moderate atopic dermatitis in patients ≥2 years old. It is the first phosphodiesterase type-4 (PDE4)…

Med Lett Drugs Ther. 2017 Feb 27; 59(1515):34-5
The FDA has approved crisaborole 2% ointment ( Eucrisa – Pfizer) for topical treatment of mild to moderate atopic dermatitis in patients ≥2 years old. It is the first phosphodiesterase type-4 (PDE4) inhibitor to be approved in the US for this indication.
Issue 1511 · January 2, 2017
Ustekinumab (Stelara) for Crohn's Disease

The FDA has approved the human interleukin (IL)-12 and -23 antagonist ustekinumab ( Stelara – Janssen Biotech) for treatment of moderately to severely active Crohn's disease in adults who were intolerant of…

Med Lett Drugs Ther. 2017 Jan 2; 59(1511):5-6
The FDA has approved the human interleukin (IL)-12 and -23 antagonist ustekinumab ( Stelara – Janssen Biotech) for treatment of moderately to severely active Crohn's disease in adults who were intolerant of or whose disease was unresponsive to treatment with immunomodulators or corticosteroids, or a tumor necrosis factor (TNF) inhibitor. Ustekinumab was approved earlier for treatment of psoriasis and psoriatic arthritis.
Issue 1494 · May 9, 2016
Ixekizumab (Taltz) - A Second IL-17A Inhibitor for Psoriasis

The FDA has approved ixekizumab ( Taltz – Lilly), an injectable humanized interleukin (IL)-17A antagonist, for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic…

Med Lett Drugs Ther. 2016 May 9; 58(1494):59-60
The FDA has approved ixekizumab ( Taltz – Lilly), an injectable humanized interleukin (IL)-17A antagonist, for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ixekizumab is the second IL-17A antagonist to be approved for this indication in the US; secukinumab ( Cosentyx – Novartis) was the first.
Issue 1492 · April 11, 2016
Calcipotriene/Betamethasone Foam (Enstilar) for Psoriasis

The FDA has approved Enstilar (Leo), an aerosol foam formulation of the synthetic vitamin D 3 analog calcipotriene and the high-potency corticosteroid betamethasone dipropionate, for topical treatment of…

Med Lett Drugs Ther. 2016 Apr 11; 58(1492):48-9
The FDA has approved Enstilar (Leo), an aerosol foam formulation of the synthetic vitamin D 3 analog calcipotriene and the high-potency corticosteroid betamethasone dipropionate, for topical treatment of plaque psoriasis in adults. Topical ointment and suspension formulations of the same combination have been available for many years.
Issue 1485 · January 4, 2016
ColciGel - A Homeopathic Colchicine Gel for Gout

Homeopathic drugs characteristically consist of very large dilutions of "proven" substances. Serial dilutions of 1:10 are designated by the Roman numeral X. ColciGel (Gensco), a prescription homeopathic gel…

Med Lett Drugs Ther. 2016 Jan 4; 58(1485):5-6
Homeopathic drugs characteristically consist of very large dilutions of "proven" substances. Serial dilutions of 1:10 are designated by the Roman numeral X. ColciGel (Gensco), a prescription homeopathic gel containing a 10,000-fold dilution of colchicine (colchicinum 4X), is now being marketed for topical treatment and prophylaxis of gout.
Issue 1481 · November 9, 2015
Budesonide Rectal Foam (Uceris) for Ulcerative Colitis

The FDA has approved a rectal foam formulation of the corticosteroid budesonide ( Uceris - Salix/Valeant) for induction of remission in patients with active mild to moderate distal ulcerative colitis (UC)…

Med Lett Drugs Ther. 2015 Nov 9; 57(1481):154
The FDA has approved a rectal foam formulation of the corticosteroid budesonide ( Uceris - Salix/Valeant) for induction of remission in patients with active mild to moderate distal ulcerative colitis (UC) extending up to 40 cm from the anal verge. Budesonide is also available as oral extended-release tablets (also branded as Uceris ) for use in patients with UC and as oral enteric-coated tablets ( Entocort EC , and generics) for treatment of Crohn's disease.
Issue 1470 · June 8, 2015
Drugs for Psoriasis

Mild to moderate psoriasis is generally treated with topical corticosteroids. Vitamin D analogs and tazarotene are topical alternatives that can be used in combination with topical corticosteroids.…

Med Lett Drugs Ther. 2015 Jun 8; 57(1470):81-4
Mild to moderate psoriasis is generally treated with topical corticosteroids. Vitamin D analogs and tazarotene are topical alternatives that can be used in combination with topical corticosteroids. Phototherapy and systemic therapy, including biologic agents, are recommended for patients with moderate to severe disease.
Issue 1470 · June 8, 2015
Drugs for Psoriatic Arthritis (online only)

Psoriatic arthritis is a chronic inflammatory arthropathy that develops in up to 40% of patients with psoriasis. Several guidelines for treatment of psoriatic arthritis have been published.

Med Lett Drugs Ther. 2015 Jun 8; 57(1470):e88-92
Psoriatic arthritis is a chronic inflammatory arthropathy that develops in up to 40% of patients with psoriasis. Several guidelines for treatment of psoriatic arthritis have been published.
Issue 1469 · May 25, 2015
Fluticasone Furoate (Arnuity Ellipta) for Asthma

The FDA has approved Arnuity Ellipta (GSK), a single-agent inhaler containing the corticosteroid fluticasone furoate, for once-daily maintenance treatment of asthma in patients ≥12 years old. Fluticasone…

Med Lett Drugs Ther. 2015 May 25; 57(1469):76-9
The FDA has approved Arnuity Ellipta (GSK), a single-agent inhaler containing the corticosteroid fluticasone furoate, for once-daily maintenance treatment of asthma in patients ≥12 years old. Fluticasone furoate is also available in combination with the long-acting beta 2 -agonist vilanterol as Breo Ellipta for treatment of asthma and COPD.
Issue 1465 · March 30, 2015
Secukinumab (Cosentyx) for Psoriasis

Secukinumab ( Cosentyx – Novartis), an injectable human interleukin (IL)-17A antagonist, has been approved by the FDA for treatment of moderate to severe plaque psoriasis in adult patients who are candidates…

Med Lett Drugs Ther. 2015 Mar 30; 57(1465):45-7
Secukinumab ( Cosentyx – Novartis), an injectable human interleukin (IL)-17A antagonist, has been approved by the FDA for treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. It is the first IL-17 inhibitor to be approved for any indication in the US.
Issue 1458 · December 22, 2014
Drugs for Rheumatoid Arthritis

For initial treatment of rheumatoid arthritis, most expert clinicians prescribe a disease-modifying antirheumatic drug (DMARD) and add a nonsteroidal anti-inflammatory drug (NSAID) or a corticosteroid to…

Med Lett Drugs Ther. 2014 Dec 22; 56(1458):127-32
For initial treatment of rheumatoid arthritis, most expert clinicians prescribe a disease-modifying antirheumatic drug (DMARD) and add a nonsteroidal anti-inflammatory drug (NSAID) or a corticosteroid to control symptoms. Methotrexate is generally the DMARD of choice... DMARDs Disease-modifying antirheumatic drugs (DMARDs) are used early in the treatment of rheumatoid arthritis (RA) to achieve clinical remission, prevent irreversible damage to joints, and minimize toxicity associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. DMARDs generally do not have an immediate analgesic effect, but over time can control symptoms and have been shown to delay and possibly stop progression of the disease. Methotrexate ( Rheumatrex , and others) is generally the first DMARD prescribed; it can be used to treat mild, moderate, or severe RA. For mild disease, some clinicians prefer to start with hydroxychloroquine ( Plaquenil , and generics) and/or sulfasalazine ( Azulfidine , and others).
Issue 1451 · September 15, 2014
Vedolizumab (Entyvio) for Inflammatory Bowel Disease

The FDA has approved vedolizumab ( Entyvio - Takeda), an intravenous integrin receptor antagonist, for treatment of moderate to severe ulcerative colitis or Crohn's disease in adults who have not responded to,…

Med Lett Drugs Ther. 2014 Sep 15; 56(1451):86-8
The FDA has approved vedolizumab ( Entyvio - Takeda), an intravenous integrin receptor antagonist, for treatment of moderate to severe ulcerative colitis or Crohn's disease in adults who have not responded to, lost response to, or cannot tolerate standard treatment. Natalizumab (Tysabri) , another integrin receptor antagonist, has been available for several years for treatment of Crohn's disease and multiple sclerosis.
Issue 1450 · September 1, 2014
Drugs for Osteoarthritis

Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Many nonpharmacologic approaches are available as well, including weight management,…

Med Lett Drugs Ther. 2014 Sep 1; 56(1450):80-4
Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Many nonpharmacologic approaches are available as well, including weight management, exercise, physical therapy, assistive devices, and total joint arthroplasty. New guidelines for the management of osteoarthritis have recently been published.
Issue 1448 · August 4, 2014
Drugs for Inflammatory Bowel Disease

Aminosalicylates are effective for induction and maintenance of remission in mild to moderate ulcerative colitis. They are not recommended for treatment of Crohn's disease. FORMULATIONS — Oral mesalamine is…

Med Lett Drugs Ther. 2014 Aug 4; 56(1448):65-72
Aminosalicylates are effective for induction and maintenance of remission in mild to moderate ulcerative colitis. They are not recommended for treatment of Crohn's disease. FORMULATIONS — Oral mesalamine is rapidly absorbed in the small intestine and most of the drug does not reach the colon. Pentasa releases mesalamine gradually throughout the gastrointestinal tract. Delzicol , Asacol HD , Lialda , and Apriso delay the release of the drug until it reaches the distal ileum and colon. Sulfasalazine ( Azulfidine , and generics), balsalazide ( Colazal , and others), and olsalazine (Dipentum) are prodrugs; mesalamine is azo-bonded to a second moiety and released in the colon following bacterial cleavage of the bond. Mesalamine is also available as an enema (Rowasa , and generics) and as a rectal suppository (Canasa) .
Issue 1439 · March 31, 2014
Golimumab (Simponi) for Ulcerative Colitis

The FDA has approved golimumab ( Simponi – Janssen), a fully human monoclonal antibody specific for tumor necrosis factor (TNF) alpha, for induction and maintenance of remission in patients with moderate to…

Med Lett Drugs Ther. 2014 Mar 31; 56(1439):25-6
The FDA has approved golimumab ( Simponi – Janssen), a fully human monoclonal antibody specific for tumor necrosis factor (TNF) alpha, for induction and maintenance of remission in patients with moderate to severe ulcerative colitis who do not respond to or cannot tolerate other therapies or who require continuous treatment with corticosteroids. Golimumab was approved earlier for treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is the third TNF inhibitor to be approved for use in ulcerative colitis.
Issue 1438 · March 17, 2014
Drugs for Gout

The goals of gout treatment are threefold: treating acute inflammation, preventing flares, and lowering serum urate levels.

Med Lett Drugs Ther. 2014 Mar 17; 56(1438):22-4
The goals of gout treatment are threefold: treating acute inflammation, preventing flares, and lowering serum urate levels.
Issue 1429 · November 11, 2013
An OTC Corticosteroid Nasal Spray for Allergic Rhinitis

The FDA has approved the over-the-counter (OTC) sale of Nasacort Allergy 24HR (Sanofi), a triamcinolone acetonide nasal spray previously available only by prescription as Nasacort AQ . The OTC product, which…

Med Lett Drugs Ther. 2013 Nov 11; 55(1429):90-1
The FDA has approved the over-the-counter (OTC) sale of Nasacort Allergy 24HR (Sanofi), a triamcinolone acetonide nasal spray previously available only by prescription as Nasacort AQ . The OTC product, which is scheduled to be marketed in the spring of 2014, will be the first corticosteroid nasal spray that can be purchased without a prescription in the US. Nasacort Allergy 24HR is approved for use in patients ≥2 years old with nasal allergy symptoms.
Issue 1423 · August 19, 2013
Canakinumab (Ilaris) for Systemic Juvenile Idiopathic Arthritis

The FDA has approved the interleukin-1 (IL-1) beta inhibitor canakinumab ( Ilaris – Novartis) for treatment of systemic juvenile idiopathic arthritis (sJIA; formerly called juvenile rheumatoid arthritis or…

Med Lett Drugs Ther. 2013 Aug 19; 55(1423):65-6
The FDA has approved the interleukin-1 (IL-1) beta inhibitor canakinumab ( Ilaris – Novartis) for treatment of systemic juvenile idiopathic arthritis (sJIA; formerly called juvenile rheumatoid arthritis or Still’s disease) in children ≥2 years old. Canakinumab was approved earlier for treatment of cryopyrin-associated periodic syndromes (CAPS). Tocilizumab (Actemra) , an interleukin-6 (IL-6) inhibitor that has been available since 2010 for treatment of rheumatoid arthritis in adults, was also recently approved by the FDA for sJIA. Canakinumab is the only IL-1 inhibitor approved for this indication.
Issue 129 · May 1, 2013
Drugs for Allergic Disorders

The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their symptoms.

Treat Guidel Med Lett. 2013 May; 11(129):43-52
The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their symptoms.
Issue 128 · April 1, 2013
Drugs for Pain

Pain can be acute or chronic. The two major types of chronic pain are nociceptive pain and neuropathic pain. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less…

Treat Guidel Med Lett. 2013 Apr; 11(128):31-42
Pain can be acute or chronic. The two major types of chronic pain are nociceptive pain and neuropathic pain. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids and is often treated with adjuvant drugs such as antidepressants and antiepileptics. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Issue 125 · January 1, 2013
Drugs for Acne, Rosacea and Psoriasis

The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens, and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium…

Treat Guidel Med Lett. 2013 Jan; 11(125):1-8
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens, and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium acnes promote development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.
Issue 117 · May 1, 2012
Drugs for Rheumatoid Arthritis

Disease-modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA) to achieve clinical remission, prevent irreversible damage to joints, and minimize toxicity…

Treat Guidel Med Lett. 2012 May; 10(117):37-44
Disease-modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA) to achieve clinical remission, prevent irreversible damage to joints, and minimize toxicity associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. DMARDs (Table 1) generally do not have an immediate analgesic effect, but over time can control symptoms and have been shown to delay and possibly stop progression of the disease. NSAIDs have immediate analgesic and antiinflammatory effects, but may not affect the disease process. Oral corticosteroids can relieve joint symptoms and control systemic manifestations, but their chronic use can cause many complications. Judicious use of intra-articular corticosteroids can rapidly decrease inflammation in acute joints with few, if any, adverse effects.
Issue 1389 · April 30, 2012
Indacaterol (Arcapta Neohaler) for COPD

The FDA has approved indacaterol (in´´ da ka´ ter ol; Arcapta Neohaler – Novartis), an inhaled long-acting beta 2 -agonist, for once-daily maintenance treatment of airflow obstruction in patients with…

Med Lett Drugs Ther. 2012 Apr 30; 54(1389):33-5
The FDA has approved indacaterol (in´´ da ka´ ter ol; Arcapta Neohaler – Novartis), an inhaled long-acting beta 2 -agonist, for once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Indacaterol is not approved for treatment of exacerbations of COPD or for treatment of asthma. It has been available in Europe as Onbrez Breezhaler since 2009.
Issue 115 · March 1, 2012
Drugs for Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is generally classified as either Crohn’s disease (CD) or ulcerative colitis (UC). More detailed guidelines on their treatment are available from the American College of…

Treat Guidel Med Lett. 2012 Mar; 10(115):19-28
Inflammatory bowel disease (IBD) is generally classified as either Crohn’s disease (CD) or ulcerative colitis (UC). More detailed guidelines on their treatment are available from the American College of Gastroenterology.
Issue 114 · February 1, 2012
Drugs for Asthma

Inhalation is the preferred route of delivery for most asthma drugs. Chlorofluorocarbons (CFCs), which have ozone-depleting properties, are being phased out as propellants in metered-dose inhalers.…

Treat Guidel Med Lett. 2012 Feb; 10(114):11-8
Inhalation is the preferred route of delivery for most asthma drugs. Chlorofluorocarbons (CFCs), which have ozone-depleting properties, are being phased out as propellants in metered-dose inhalers. Non-chlorinated hydrofluoroalkane (HFA) propellants, which do not deplete the ozone layer, are being used instead.
Issue 1376 · October 31, 2011
A Fixed-Dose Combination of Ibuprofen and Famotidine (Duexis)

The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of…

Med Lett Drugs Ther. 2011 Oct 31; 53(1376):85-6
The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of osteoarthritis and rheumatoid arthritis and to decrease the risk of developing gastric and duodenal ulcers in patients at risk for NSAID-associated ulcers. Vimovo , a combination of the NSAID naproxen and the proton pump inhibitor (PPI) esomeprazole, is also approved by the FDA for prevention of NSAID-associated gastric ulcers.
Issue 1369 · July 25, 2011
Roflumilast (Daliresp) for COPD

Roflumilast ( Daliresp – Forest), an oral phosphodiesterase 4 (PDE4) inhibitor, was approved by the FDA to reduce the risk of exacerbations in adult patients with severe chronic obstructive pulmonary disease…

Med Lett Drugs Ther. 2011 Jul 25; 53(1369):59-60
Roflumilast ( Daliresp – Forest), an oral phosphodiesterase 4 (PDE4) inhibitor, was approved by the FDA to reduce the risk of exacerbations in adult patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.
Issue 99 · November 1, 2010
Drugs for Chronic Obstructive Pulmonary Disease

The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and decrease complications of the disease such…

Treat Guidel Med Lett. 2010 Nov; 8(99):83-8
The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and decrease complications of the disease such as acute exacerbations. Other guidelines for treatment of this condition have been published or updated in recent years.
Issue 1349 · October 18, 2010
Mometasone/Formoterol (Dulera) for Asthma

A combination of the corticosteroid mometasone furoate (Asmanex) and the long-acting beta 2 -agonist (LABA) formoterol (Foradil) has become available in a single metered-dose inhaler ( Dulera – Schering) for…

Med Lett Drugs Ther. 2010 Oct 18; 52(1349):83-4
A combination of the corticosteroid mometasone furoate (Asmanex) and the long-acting beta 2 -agonist (LABA) formoterol (Foradil) has become available in a single metered-dose inhaler ( Dulera – Schering) for treatment of asthma in patients ≥12 years old. It is the third corticosteroid/LABA combination inhaler to become available for this indication in the US. None of these combinations should be used for initial treatment of asthma or for acute treatment of asthma symptoms.
Issue 94 · June 1, 2010
Drugs for Bacterial Infections

The text below reviews some common bacterial infections and their treatment. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter…

Treat Guidel Med Lett. 2010 Jun; 8(94):43-52
The text below reviews some common bacterial infections and their treatment. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants.
Issue 1339 · May 31, 2010
Safety of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (COPD)

Two combinations of an inhaled corticosteroid with an inhaled long-acting beta2-agonist are approved by the FDA for use in patients with COPD: fluticasone/salmeterol (Advair Diskus) and budesonide/formoterol…

Med Lett Drugs Ther. 2010 May 31; 52(1339):41-2
Two combinations of an inhaled corticosteroid with an inhaled long-acting beta2-agonist are approved by the FDA for use in patients with COPD: fluticasone/salmeterol (Advair Diskus) and budesonide/formoterol (Symbicort) . A Medical Letter reader has questioned the safety of using corticosteroid inhalers in patients with this disorder. No single-agent inhaled corticosteroid inhaler is approved for this indication.
Issue 92 · April 1, 2010
Drugs for Pain

Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is…

Treat Guidel Med Lett. 2010 Apr; 8(92):25-34
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids; adjuvant medicines such as antidepressants and anticonvulsants are often used to treat neuropathic pain. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Issue 1334 · March 22, 2010 Free
In Brief: Stopping Long-Acting Beta-2 Agonists

A little more than a year ago, The Medical Letter reported the results of an FDA meta-analysis which found that use of a long-acting beta-2 agonist (LABA) such as salmeterol (Severent) or formoterol (Foradil)…

Med Lett Drugs Ther. 2010 Mar 22; 52(1334):21
A little more than a year ago, The Medical Letter reported the results of an FDA meta-analysis which found that use of a long-acting beta-2 agonist (LABA) such as salmeterol (Severent) or formoterol (Foradil) in patients with asthma was associated with an increased risk of a composite endpoint of asthma-related death, intubation or hospitalization; the highest risk was in children 4-11 years old.There was no significant increase in risk when a long-acting beta-2 agonist was used with an inhaled corticosteroid.The Medical Letter recommended that long-acting beta-2 agonists should not be used as monotherapy for asthma, especially in children, and that long-acting beta-2 agonists should be used for asthma only in combination with an inhaled corticosteroid, preferably in a fixed-dose combination in the same inhaler. 1 Now the FDA has issued new Safe Use Requirements 2 and labeling requirements for long-acting beta-2 agonists that include the following: “Stop use of the LABA, if possible, once asthma control is achieved and maintain the use of an asthma-controller medication such as an inhaled corticosteroid.” 3 It has not been determined that patients taking a longacting beta-2 agonist in a fixed-dose combination with an inhaled corticosteroid have an increased risk of death or that stopping long-acting beta-2 agonists in such patients will improve long-term outcomes. A controlled clinical trial of these new requirements would be welcome. 1. Long-acting beta-2 agonists in asthma. Med Lett Drugs Ther 2009; 51:1. 2. www.fda.gov/safety/medwatch/default.htm 3. BA Chowdhury and G Dal Pan. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010; Feb 24 (epub). Download: U.S. English
Issue 1333 · March 8, 2010 Free
Addendum: Cost of Ustekinumab (Stelara)

In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7) , footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.

Med Lett Drugs Ther. 2010 Mar 8; 52(1333):20
In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7) , footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.
Issue 90 · February 1, 2010
Drugs for Allergic Disorders

Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (not included here; reviewed in Treatment Guidelines 2008; 6:83 ) are prevalent worldwide, especially in…

Treat Guidel Med Lett. 2010 Feb; 8(90):9-18
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (not included here; reviewed in Treatment Guidelines 2008; 6:83 ) are prevalent worldwide, especially in industrialized countries. Pharmacologic treatment of these disorders continues to improve in efficacy and safety. In addition to using drugs to prevent and control these allergic diseases, patients should be instructed to avoid, if possible, specific allergens and/or environmental conditions that trigger or worsen their symptoms. Allergen-specific immunotherapy may be useful for treatment of allergic rhinitis and allergic conjunctivitis, and in preventing severe insect venom-triggered reactions.
Issue 1330 · January 25, 2010
Ustekinumab (Stelara) for Psoriasis

The FDA has approved the use of ustekinumab ( Stelara - Centocor Ortho Biotech), an interleukin antagonist given by subcutaneous (SC) injection for treatment of adults with moderate to severe plaque psoriasis.…

Med Lett Drugs Ther. 2010 Jan 25; 52(1330):7-8
The FDA has approved the use of ustekinumab ( Stelara - Centocor Ortho Biotech), an interleukin antagonist given by subcutaneous (SC) injection for treatment of adults with moderate to severe plaque psoriasis. It is the first agent in its class for this indication; the other biologic agents for psoriasis are Tcell or tumor necrosis factor (TNF) inhibitors.
Issue 1326 · November 30, 2009
Colchicine and Other Drugs for Gout

Until the recent introduction of febuxostat (Uloric) , no new drugs had been marketed for treatment of gout in the past 40 years. Colchicine, which has been available for decades as an unapproved drug, has now…

Med Lett Drugs Ther. 2009 Nov 30; 51(1326):93-4
Until the recent introduction of febuxostat (Uloric) , no new drugs had been marketed for treatment of gout in the past 40 years. Colchicine, which has been available for decades as an unapproved drug, has now been approved by the FDA (Colcrys) for treatment and prophylaxis of gout flares. It was approved earlier only in combination with probenecid ( Colbenemid , and others). The goals of gout treatment are three-fold: treating acute disease, preventing flares and reducing uric acid stores.
Issue 85 · September 1, 2009
Drugs for Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is either Crohn's disease or ulcerative colitis. Drug selection is guided by disease type (Crohn's versus ulcerative colitis), severity and location and whether the goal is…

Treat Guidel Med Lett. 2009 Sep; 7(85):65-74
Inflammatory bowel disease (IBD) is either Crohn's disease or ulcerative colitis. Drug selection is guided by disease type (Crohn's versus ulcerative colitis), severity and location and whether the goal is induction or maintenance of remission. Table 1 on page 66 lists the drugs used to treat IBD with their formulations and cost. Table 2 on page 68 lists the drugs of choice and their doses for different indications. Table 3 on page 71 lists the drugs' adverse effects and recommendations for monitoring. More detailed guidelines are available from the American College of Gastroenterology.
Issue 84 · August 1, 2009
Drugs for Thyroid Disorders

Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.

Treat Guidel Med Lett. 2009 Aug; 7(84):57-64
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Issue 1312 · May 18, 2009
Febuxostat (Uloric) for Chronic Treatment of Gout

Febuxostat ( Uloric - Takeda), a xanthine oxidase inhibitor, has been approved by the FDA for chronic management of hyperuricemia in patients with gout. It is the first drug marketed for treatment of gout in…

Med Lett Drugs Ther. 2009 May 18; 51(1312):37-8
Febuxostat ( Uloric - Takeda), a xanthine oxidase inhibitor, has been approved by the FDA for chronic management of hyperuricemia in patients with gout. It is the first drug marketed for treatment of gout in 40 years. Febuxostat is structurally unrelated to allopurinol, the only other commercially available inhibitor of xanthine oxidase. Xanthine oxidase inhibitors decrease serum urate concentrations by decreasing urate synthesis.
Issue 81 · May 1, 2009
Drugs for Rheumatoid Arthritis

Disease-modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA) to prevent irreversible damage to joints and minimize toxicities associated with nonsteroidal…

Treat Guidel Med Lett. 2009 May; 7(81):37-46
Disease-modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA) to prevent irreversible damage to joints and minimize toxicities associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.
Issue 1305 · February 9, 2009
Two New Drugs for Chronic ITP

Romiplostim ( Nplate - Amgen), a recombinant fusion protein injected subcutaneously, and eltrombopag ( Promacta - GlaxoSmithKline), a non-peptide taken orally, have been approved by the FDA for treatment of…

Med Lett Drugs Ther. 2009 Feb 9; 51(1305):10-1
Romiplostim ( Nplate - Amgen), a recombinant fusion protein injected subcutaneously, and eltrombopag ( Promacta - GlaxoSmithKline), a non-peptide taken orally, have been approved by the FDA for treatment of chronic immune thrombocytopenic purpura (ITP) refractory to corticosteroids, immunoglobulins and/or splenectomy.
Issue 1303 · January 12, 2009
Long-Acting Beta-2 Agonists in Asthma

Continued use of a long-acting beta-2 agonist for treatment of asthma may cause down-regulation of the beta-2 receptor with loss of the bronchoprotective effect from rescue therapy with a short-acting beta-2…

Med Lett Drugs Ther. 2009 Jan 12; 51(1303):1-2
Continued use of a long-acting beta-2 agonist for treatment of asthma may cause down-regulation of the beta-2 receptor with loss of the bronchoprotective effect from rescue therapy with a short-acting beta-2 agonist. After a large study (SMART) found an increased risk of asthma-related deaths in patients receiving the long-acting beta-2 agonist salmeterol, a boxed warning was added to the labeling of all medications containing a long-acting beta-2 agonist. Now the FDA has completed a meta-analysis of 110 asthma treatment studies in 60,954 patients taking any of the long-acting beta-2 agonist formulations listed in the table.
Issue 1301 · December 15, 2008 Free
Drugs That May Cause Psychiatric Symptoms

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness,…

Med Lett Drugs Ther. 2008 Dec 15; 50(1301):100-3
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression. Click here to view the free full article.
Issue 1301 · December 15, 2008
A Granisetron Patch (Sancuso)

The treatment of choice to prevent emesis due to highand moderate-risk emetogenic drugs used in cancer chemotherapy is aprepitant plus a serotonin receptor antagonist plus dexamethasone. Four serotonin…

Med Lett Drugs Ther. 2008 Dec 15; 50(1301):103-0
The treatment of choice to prevent emesis due to highand moderate-risk emetogenic drugs used in cancer chemotherapy is aprepitant plus a serotonin receptor antagonist plus dexamethasone. Four serotonin receptor antagonists are available in the US in intravenous (IV) formulations for prevention of nausea and vomiting due to cancer chemotherapy, and 3 of these are also available for oral use. Now the FDA has approved one of these, granisetron, in a transdermal formulation ( Sancuso - ProStrakan).
Issue 76 · December 1, 2008
Drugs for Asthma

No truly new drugs have been approved for treatment of asthma since omalizumab (Xolair) in 2003, but some randomized controlled trials of older drugs have been published, and new guidelines have become…

Treat Guidel Med Lett. 2008 Dec; 6(76):83-90
No truly new drugs have been approved for treatment of asthma since omalizumab (Xolair) in 2003, but some randomized controlled trials of older drugs have been published, and new guidelines have become available.
Issue 75 · November 1, 2008
Drugs for Acne, Rosacea and Psoriasis

The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium…

Treat Guidel Med Lett. 2008 Nov; 6(75):75-82
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium acnes promote development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.
Issue 1289 · June 30, 2008
Olopatadine (Patanase) Nasal Spray

Olopatadine 0.6% nasal spray ( Patanase - Alcon) has been approved by the FDA for treatment of seasonal allergic rhinitis in patients ≥ 12 years old. An H1-antihistamine with mast-cell stabilizing activity,…

Med Lett Drugs Ther. 2008 Jun 30; 50(1289):51-2
Olopatadine 0.6% nasal spray ( Patanase - Alcon) has been approved by the FDA for treatment of seasonal allergic rhinitis in patients ≥ 12 years old. An H1-antihistamine with mast-cell stabilizing activity, olopatadine is already marketed for treatment of allergic conjunctivitis in a 0.1% solution as Patanol and in a 0.2% solution as Pataday. Azelastine (Astelin) , another H1-antihistamine with mast-cell stabilizing activity, has been available for intranasal treatment of allergic rhinitis since 1997.
Issue 1273 · November 5, 2007
Fluticasone Furoate (Veramyst) for Allergic Rhinitis

Fluticasone furoate nasal spray ( Veramyst - GSK) is now available for once-daily treatment of seasonal and perennial allergic rhinitis in adults and children ≥2 years old. It is similar to fluticasone…

Med Lett Drugs Ther. 2007 Nov 5; 49(1273):90-2
Fluticasone furoate nasal spray ( Veramyst - GSK) is now available for once-daily treatment of seasonal and perennial allergic rhinitis in adults and children ≥2 years old. It is similar to fluticasone propionate nasal spray ( Flonase , and others), which is now available generically.
Issue 63 · November 1, 2007
Drugs for Chronic Obstructive Pulmonary Disease

The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and minimize complications of the disease such…

Treat Guidel Med Lett. 2007 Nov; 5(63):95-100
The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and minimize complications of the disease such as acute exacerbations and cor pulmonale. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines developed by the World Health Organization and the National Heart, Lung and Blood Institute were updated in 2006. The American Thoracic Society and the European Respiratory Society jointly developed guidelines for COPD in 2004.
Issue 57 · May 1, 2007
Choice of Antibacterial Drugs

Information about empirical treatment of bacterial infections, emerging trends in antimicrobial resistance, new drugs and new data about older drugs continue to become available. Usual pathogens and empiric…

Treat Guidel Med Lett. 2007 May; 5(57):33-50
Information about empirical treatment of bacterial infections, emerging trends in antimicrobial resistance, new drugs and new data about older drugs continue to become available. Usual pathogens and empiric treatment for some common types of infections are summarized in the text and a table listing the drugs of choice and alternatives for each pathogen begins on page 40. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants.
Issue 56 · April 1, 2007
Drugs for Pain

Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain is generally treated with nonopioid analgesics and opioids. Antidepressants…

Treat Guidel Med Lett. 2007 Apr; 5(56):23-32
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain is generally treated with nonopioid analgesics and opioids. Antidepressants and anticonvulsants have been used to treat neuropathic pain. Combining two different types of analgesics may nprovide an additive analgesic effect without increasing adverse effects.
Issue 1238 · July 3, 2006
A Betamethasone-Calcipotriene Combination for Psoriasis

Taclonex ointment (Warner Chilcott/LEO Pharma), a combination of the vitamin D3 analog calcipotriene 0.005% (Dovonex) and the high-potency corticosteroid betamethasone dipropionate 0.064%, was recently…

Med Lett Drugs Ther. 2006 Jul 3; 48(1238):55-6
Taclonex ointment (Warner Chilcott/LEO Pharma), a combination of the vitamin D3 analog calcipotriene 0.005% (Dovonex) and the high-potency corticosteroid betamethasone dipropionate 0.064%, was recently approved by the FDA for treatment of psoriasis vulgaris in patients ≥ 18 years old.
Issue 1231 · March 27, 2006
Intra-Articular Injections for Osteoarthritis of the Knee

Now that glucosamine and chondroitin, 2 favorite over-the-counter remedies for painful osteoarthritis (OA) of the knee, have been at least somewhat discredited, some patients will be asking about alternatives.…

Med Lett Drugs Ther. 2006 Mar 27; 48(1231):25-7
Now that glucosamine and chondroitin, 2 favorite over-the-counter remedies for painful osteoarthritis (OA) of the knee, have been at least somewhat discredited, some patients will be asking about alternatives. One of these is periodic intra-articular injection of a corticosteroid or hyaluronic acid preparation.
Issue 1231 · March 27, 2006
Clobetasol Propionate (Clobex) Spray for Psoriasis

The FDA has approved a new spray formulation of the super-high-potency corticosteroid clobetasol propionate 0.05% ( Clobex - Galderma) for treatment of moderate to severe plaque psoriasis in adults. Clobetasol…

Med Lett Drugs Ther. 2006 Mar 27; 48(1231):27-8
The FDA has approved a new spray formulation of the super-high-potency corticosteroid clobetasol propionate 0.05% ( Clobex - Galderma) for treatment of moderate to severe plaque psoriasis in adults. Clobetasol propionate is also available as a cream, ointment, gel, solution, foam, lotion and shampoo.
Issue 1223 · December 5, 2005
Mometasone (Asmanex Twisthaler) for Asthma

The FDA has approved marketing of the corticosteroid mometasone furoate in an orally inhaled dry powder formulation ( Asmanex Twisthaler - Schering-Plough) for maintenance treatment of asthma in patients at…

Med Lett Drugs Ther. 2005 Dec 5; 47(1223):98-9
The FDA has approved marketing of the corticosteroid mometasone furoate in an orally inhaled dry powder formulation ( Asmanex Twisthaler - Schering-Plough) for maintenance treatment of asthma in patients at least 12 years old. Mometasone is also available as a mid-potency topical corticosteroid cream ( Elocon ) and as an intranasal spray ( Nasonex ) for treatment of allergic rhinitis.
Issue 40 · December 1, 2005
Drugs for Rheumatoid Arthritis

To prevent irreversible damage to joints and minimize toxicities associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, disease modifying anti-rheumatic drugs (DMARDs) are now used…

Treat Guidel Med Lett. 2005 Dec; 3(40):83-90
To prevent irreversible damage to joints and minimize toxicities associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, disease modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA). The DMARDs listed in the table on page 84 have no immediate analgesic effects, but can control symptoms and have been shown to delay and possibly stop progression of the disease. The NSAIDs listed in the table on page 88 have analgesic and anti-inflammatory effects, but may not affect the disease process. Oral corticosteroids can rapidly relieve joint symptoms and control systemic manifestations, but their chronic use is associated with many complications.
Issue 35 · July 1, 2005
Drugs for Acne, Rosacea and Psoriasis

The pathogenesis of acne is multifactorial: follicular hyperkeratinization, Propionibacterium acnes bacteria , sebum production, androgens and inflammation have all been implicated. P. acnes , a gram-positive…

Treat Guidel Med Lett. 2005 Jul; 3(35):49-56
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, Propionibacterium acnes bacteria , sebum production, androgens and inflammation have all been implicated. P. acnes , a gram-positive microaerophilic bacterium, plays an important role in the development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.
Issue 33 · May 1, 2005
Drugs for Asthma

Patients with mild, infrequent asthma symptoms may require only intermittent, asneeded use of an inhaled short-acting beta2-adrenergic agonist. Use of a short-acting beta2-agonist more than twice weekly, other…

Treat Guidel Med Lett. 2005 May; 3(33):33-8
Patients with mild, infrequent asthma symptoms may require only intermittent, asneeded use of an inhaled short-acting beta2-adrenergic agonist. Use of a short-acting beta2-agonist more than twice weekly, other than for exercise-induced bronchospasm, indicates a need for anti-inflammatory treatment. Inhaled corticosteroids are the most effective anti-inflammatory medication; leukotriene modifiers are less effective alternatives. If regular use of an inhaled corticosteroid in a low dose does not prevent symptoms, a long-acting beta2-agonist should be added; addition of a second drug is more effective than raising the dose of the inhaled steroid. A leukotriene modifier can also be used as the second drug. Omalizumab may be considered as adjunctive therapy for patients more than 12 years old who have allergic asthma not controlled by other drugs. A short course of oral corticosteroids may be useful for acute exacerbations. Treatment of acute severe asthma as a medical emergency is not included here; it has been reviewed elsewhere (ER McFadden Jr, Am J Respir Crit Care Med 2003; 168:740) .
Issue 23 · July 1, 2004
Drugs for Pain

Three types of analgesic drugs are available: non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; opioids; and adjuvant drugs that are not usually thought of…

Treat Guidel Med Lett. 2004 Jul; 2(23):47-54
Three types of analgesic drugs are available: non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; opioids; and adjuvant drugs that are not usually thought of as analgesics, such as antidepressants, which can act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. Combining two different types of analgesics may provide an additive analgesic effect without necessarily increasing adverse effects.
Issue 1184 · June 7, 2004 Free
Prevention and Treatment of Sunburn

Solar ultraviolet (UV) light capable of injuring the skin is classified by wavelength into UVA I (340-400 nm), UVA II (320-340 nm) and UVB (290-320 nm). UVB is responsible for most of the erythema of sunburn.…

Med Lett Drugs Ther. 2004 Jun 7; 46(1184):45-6
Solar ultraviolet (UV) light capable of injuring the skin is classified by wavelength into UVA I (340-400 nm), UVA II (320-340 nm) and UVB (290-320 nm). UVB is responsible for most of the erythema of sunburn. UVA has been implicated in the development of phototoxicity and photoaging. The FDA permits sunscreen manufacturers to claim broad-spectrum protection if their products block at least part of UVA II in addition to UVB. Click here to view the free full article.
Issue 19 · March 1, 2004
Choice of Antibacterial Drugs

New drugs for bacterial infections and new information about older drugs continue to become available. Empirical treatment of some common bacterial infections is discussed in this article. A table listing the…

Treat Guidel Med Lett. 2004 Mar; 2(19):13-22
New drugs for bacterial infections and new information about older drugs continue to become available. Empirical treatment of some common bacterial infections is discussed in this article. A table listing the drugs of choice and alternatives for each pathogen begins on page 18. These recommendations are based on results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants. Local resistance patterns should be taken into account. Trade names are listed on page 24.
Issue 1163 · August 19, 2003
Omalizumab (Xolair): An Anti-IgE Antibody For Asthma

The FDA has approved release of omalizumab (oh mah lye zoo mab; Xolair - Genentech, Novartis), a humanized monoclonal antibody given subcutaneously that binds to immunoglobulin E (IgE). The drug is labeled for…

Med Lett Drugs Ther. 2003 Aug 19; 45(1163):67-8
The FDA has approved release of omalizumab (oh mah lye zoo mab; Xolair - Genentech, Novartis), a humanized monoclonal antibody given subcutaneously that binds to immunoglobulin E (IgE). The drug is labeled for patients at least 12 years old with moderate to severe persistent asthma who have shown reactivity to an allergen and whose symptoms are inadequately controlled by an inhaled corticosteroid. The manufacturer claims the drug can help stop allergic reactions before they begin.
Issue 1162 · August 4, 2003
Aprepitant (Emend) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

Aprepitant ( Emend - Merck), the first substance P/neurokinin 1 (NK 1 ) receptor antagonist to be approved by the FDA, is now available for oral use with corticosteroids and selective serotonin (5-HT 3 )…

Med Lett Drugs Ther. 2003 Aug 4; 45(1162):62-3
Aprepitant ( Emend - Merck), the first substance P/neurokinin 1 (NK 1 ) receptor antagonist to be approved by the FDA, is now available for oral use with corticosteroids and selective serotonin (5-HT 3 ) receptor antagonists to prevent nausea and vomiting caused by highly emetogenic anticancer drugs such as cisplatin.
Issue 1154 · April 14, 2003
Alefacept (Amevive) For Treatment of Psoriasis

Alefacept (a le' fa sept; Amevive - Biogen) has been approved by the FDA for parenteral treatment of adults with moderate to severe chronic plaque psoriasis.

Med Lett Drugs Ther. 2003 Apr 14; 45(1154):31-2
Alefacept (a le' fa sept; Amevive - Biogen) has been approved by the FDA for parenteral treatment of adults with moderate to severe chronic plaque psoriasis.
Issue 1152 · March 17, 2003
Montelukast (Singulair) for Allergic Rhinitis

Montelukast ( Singulair - Merck), a leukotriene receptor antagonist already marketed for asthma ( Treatment Guidelines from The Medical Letter 2002; 1:11 ), has been approved by the FDA for treatment of…

Med Lett Drugs Ther. 2003 Mar 17; 45(1152):21-2
Montelukast ( Singulair - Merck), a leukotriene receptor antagonist already marketed for asthma ( Treatment Guidelines from The Medical Letter 2002; 1:11 ), has been approved by the FDA for treatment of seasonal allergic rhinitis in adults and children more than 2 years old.
Issue 5 · January 1, 2003
Drugs for Rheumatoid Arthritis

Many different drugs are now used to treat rheumatoid arthritis. Nonsteroidal anti-inflammatory drugs (NSAIDs), listed in the table on page 26, have analgesic and anti-inflammatory effects, but may not affect…

Treat Guidel Med Lett. 2003 Jan; 1(5):25-32
Many different drugs are now used to treat rheumatoid arthritis. Nonsteroidal anti-inflammatory drugs (NSAIDs), listed in the table on page 26, have analgesic and anti-inflammatory effects, but may not affect the disease process. Corticosteroids can provide rapid relief of joint symptoms and control of systemic manifestations, but chronic use is associated with many complications. The "disease-modifying" anti-rheumatic drugs (DMARDs), listed on page 29, have no immediate analgesic effects, but can control symptoms and may delay progression of the disease (American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines, Arthritis Rheum 2002; 46:328). Interactions of anti-rheumatic drugs with other drugs are listed in The Medical Letter Handbook of Adverse Drug Interactions, 2003.
Issue 2 · October 1, 2002
Drugs for Asthma

New drug formulations continue to be introduced for the treatment of asthma, and new studies on older drugs continue to change our perspectives on the management of this chronic inflammatory disease. Treatment…

Treat Guidel Med Lett. 2002 Oct; 0(2):7-12
New drug formulations continue to be introduced for the treatment of asthma, and new studies on older drugs continue to change our perspectives on the management of this chronic inflammatory disease. Treatment of asthma in the emergency department or hospital is not addressed here. More information on the diagnosis and treatment of asthma is available from Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma (Bethesda:NIH, 1997 and 2002 update; www.nhlbi.nih.gov ).
Issue 1134 · July 8, 2002
Drugs That May Cause Psychiatric Symptoms

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment may also be due to the underlying illness, previously…

Med Lett Drugs Ther. 2002 Jul 8; 44(1134):59-62
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment may also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.
Issue 1131 · May 27, 2002
Topical Pimecrolimus (Elidel) for treatment of atopic dermatitis

Pimecrolimus 1% cream (pim e kroe' limus; SDZ ASM 981; Elidel - Novartis) has been approved by the FDA for short-term and intermittent long-term treatment of mild to moderate atopic dermatitis in…

Med Lett Drugs Ther. 2002 May 27; 44(1131):48-50
Pimecrolimus 1% cream (pim e kroe' limus; SDZ ASM 981; Elidel - Novartis) has been approved by the FDA for short-term and intermittent long-term treatment of mild to moderate atopic dermatitis in non-immunocompromised patients at least 2 years old.
Issue 1122 · January 21, 2002
Budesonide (Entocort EC) For Crohn's Disease

Budesonide ( Entocort EC — AstraZeneca), a locally active glucocorticosteriod widely used for inhalation treatment of allergic rhinitis and asthma (Medical Letter 2000; 42:19) , has been approved for oral…

Med Lett Drugs Ther. 2002 Jan 21; 44(1122):6-8
Budesonide ( Entocort EC — AstraZeneca), a locally active glucocorticosteriod widely used for inhalation treatment of allergic rhinitis and asthma (Medical Letter 2000; 42:19) , has been approved for oral treatment of mild to moderate active Crohn's disease involving the ileum and/or ascending colon. Both oral budesonide and budesonide enemas have been available for years in Europe and Canada for treatment of inflammatory bowel disease.
Issue 1102 · April 16, 2001
A Combination of Fluticasone and Salmeterol For Asthma

Fluticasone propionate, an inhaled corticosteroid, and salmeterol xinafoate, a long-acting beta2-adrenergic agonist, are now available together in a dry-powder inhaler for maintenance treatment of patients…

Med Lett Drugs Ther. 2001 Apr 16; 43(1102):31-3
Fluticasone propionate, an inhaled corticosteroid, and salmeterol xinafoate, a long-acting beta2-adrenergic agonist, are now available together in a dry-powder inhaler for maintenance treatment of patients with asthma. The new combination is not recommended for treatment of acute bronchospasm or for treatment of children less than 12 years old.
Issue 1102 · April 16, 2001
Topical Tacrolimus For Treatment of Atopic Dermatitis

Tacrolimus ointment (Protopic) has been approved by the FDA in 0.03% and 0.1% formulations for treatment of atopic dermatitis. Tacrolimus is used systemically (Prograf) to prevent rejection of organ…

Med Lett Drugs Ther. 2001 Apr 16; 43(1102):33-4
Tacrolimus ointment (Protopic) has been approved by the FDA in 0.03% and 0.1% formulations for treatment of atopic dermatitis. Tacrolimus is used systemically (Prograf) to prevent rejection of organ transplants.
Issue 1093 · November 27, 2000
Drugs that may cause Cognitive Disorders in the Elderly

Older patients are especially susceptible to drug-induced cognitive impairment. They are more likely to be taking multiple drugs, to have higher blood levels of those drugs because of renal or hepatic…

Med Lett Drugs Ther. 2000 Nov 27; 42(1093):111-2
Older patients are especially susceptible to drug-induced cognitive impairment. They are more likely to be taking multiple drugs, to have higher blood levels of those drugs because of renal or hepatic dysfunction, and to have pre-existing cognitive problems that make it difficult to detect the role of drugs causing new symptoms or making old ones worse.
Issue 1085 · August 21, 2000
Drugs for Pain

Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought…

Med Lett Drugs Ther. 2000 Aug 21; 42(1085):73-8
Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought of as analgesics, which act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. Non-opioids can be given concurrently with opioids for an additive analgesic effect.
Issue 1082 · July 10, 2000
Drugs For Rheumatoid Arthritis

Many different drugs are now used to treat rheumatoid arthritis. Nonsteroidal anti-inflammatory drugs (NSAIDs) have analgesic and anti-inflammatory effects, but may not affect the disease process. The…

Med Lett Drugs Ther. 2000 Jul 10; 42(1082):57-64
Many different drugs are now used to treat rheumatoid arthritis. Nonsteroidal anti-inflammatory drugs (NSAIDs) have analgesic and anti-inflammatory effects, but may not affect the disease process. The "disease-modifying anti-rheumatic"drugs (DMARDs) have no immediate analgesic effects, but can control symptoms and may delay progression of the disease.
Issue 1075 · April 3, 2000
Bexarotene (Targretin) For Cutaneous T-cell Lymphoma

Bexarotene, a retinoid analog, has been approved by the US Food and Drug Administration for oral treatment of dermatologic manifestations of refractory cutaneous T-cell lymphoma.

Med Lett Drugs Ther. 2000 Apr 3; 42(1075):31-2
Bexarotene, a retinoid analog, has been approved by the US Food and Drug Administration for oral treatment of dermatologic manifestations of refractory cutaneous T-cell lymphoma.
Issue 1073 · March 6, 2000
Drugs for Asthma

Asthma is a chronic inflammatory disorder of the airways; inflammation caused by allergens, viral respiratory infections or other stimuli leads to bronchial hyperresponsiveness and obstruction of airflow.…

Med Lett Drugs Ther. 2000 Mar 6; 42(1073):19-24
Asthma is a chronic inflammatory disorder of the airways; inflammation caused by allergens, viral respiratory infections or other stimuli leads to bronchial hyperresponsiveness and obstruction of airflow. Anti-inflammatory drugs, particularly inhaled corticosteroids, are central to its management.
Issue 958 · September 29, 1995
Mycophenolate Mofetil - A New Immunosuppressant for Organ Transplantation

Mycophenolate mofetil ( CellCept - Roche) has been approved by the US Food and Drug Administration for oral use in preventing organ rejection in patients receiving allogeneic renal transplants. It is being…

Med Lett Drugs Ther. 1995 Sep 29; 37(958):84-6
Mycophenolate mofetil ( CellCept - Roche) has been approved by the US Food and Drug Administration for oral use in preventing organ rejection in patients receiving allogeneic renal transplants. It is being promoted as an improvement over azathioprine (Imuran) for concurrent use with cyclosporine (Sandimmune; Neoral) and corticosteroids.
Issue 954 · August 4, 1995
Drugs For Tuberculosis

Tuberculosis (TB) continues to be a major problem in the United States, particularly in areas where drug resistance is common (Morbid Mortal Weekly Rep, 44:387, May 26, 1995). Since poor compliance is the most…

Med Lett Drugs Ther. 1995 Aug 4; 37(954):67-70
Tuberculosis (TB) continues to be a major problem in the United States, particularly in areas where drug resistance is common (Morbid Mortal Weekly Rep, 44:387, May 26, 1995). Since poor compliance is the most important cause of treatment failure and is associated with emergence of drug resistence, some experts now recommend that all patients take drugs for TB under direct observation (SE Weis et al, N Engl J Med, 330:1179, 1994; R Bayer and D Wilkinson, Lancet, 345:1545, June 17, 1995).
Issue 940 · January 20, 1995
Fluticasone Propionate Nasal Spray for Allergic Rhinitis

An intranasal spray formulation of the corticosteroid fluticasone propionate (floo tik a sone; Flonase - Allen & Hanburys) has been approved by the US Food and Drug Administration for treatment of seasonal and…

Med Lett Drugs Ther. 1995 Jan 20; 37(940):5-6
An intranasal spray formulation of the corticosteroid fluticasone propionate (floo tik a sone; Flonase - Allen & Hanburys) has been approved by the US Food and Drug Administration for treatment of seasonal and perennial allergic rhinitis in adults and children more than 12 years old.
Issue 934 · October 28, 1994
Doxepin Cream for Pruritus

The US Food and Drug Administration has approved the marketing of 5% doxepin hydrochloride cream ( Zonalon - GenDerm) for treatment of pruritus due to eczematous dermatoses. Oral doxepin is used as a tricyclic…

Med Lett Drugs Ther. 1994 Oct 28; 36(934):99-100
The US Food and Drug Administration has approved the marketing of 5% doxepin hydrochloride cream ( Zonalon - GenDerm) for treatment of pruritus due to eczematous dermatoses. Oral doxepin is used as a tricyclic antidepressant ( Sinequan , and others).
Issue 928 · August 5, 1994
Calcipotriene for Psoriasis

Calcipotriene ointment 0.005% (calcipotriol; Dovonex - Westwood Squibb), a synthetic vitamin D 3 analog previously available in Europe and Canada, has now been approved by the US Food and Drug Administration…

Med Lett Drugs Ther. 1994 Aug 5; 36(928):70-1
Calcipotriene ointment 0.005% (calcipotriol; Dovonex - Westwood Squibb), a synthetic vitamin D 3 analog previously available in Europe and Canada, has now been approved by the US Food and Drug Administration (FDA) for treatment of moderate plaque psoriasis, the most common form of the disease.
Issue 926 · July 8, 1994
Granisetron to Prevent Vomiting After Cancer Chemotherapy

Granisetron, a serotonin (5-HT) antagonist similar to ondansetron, was recently approved by the US Food and Drug Administration for prevention of nausea and vomiting due to cancer chemotherapy. Although…

Med Lett Drugs Ther. 1994 Jul 8; 36(926):61-2
Granisetron, a serotonin (5-HT) antagonist similar to ondansetron, was recently approved by the US Food and Drug Administration for prevention of nausea and vomiting due to cancer chemotherapy. Although available in an oral formulation in other countries, granisetron is available here only for intravenous (IV) use.
Issue 926 · July 8, 1994
Intranasa Budesonide for Allergic Rhinitis

An intranasal formulation of the corticosteroid budesonide ( Rhinocort Nasal Inhaler - Astra) was recently approved by the US Food and Drug Administration for treatment of seasonal or perennial allergic…

Med Lett Drugs Ther. 1994 Jul 8; 36(926):63-4
An intranasal formulation of the corticosteroid budesonide ( Rhinocort Nasal Inhaler - Astra) was recently approved by the US Food and Drug Administration for treatment of seasonal or perennial allergic rhinitis in adults and children and nonallergic perennial rhinitis in adults. Budesonide has been available in Canada and Europe for several years for inhalation treatment of both allergic rhinitis and asthma.
Issue 921 · April 29, 1994
Salmeterol

Salmeterol xinafoate ( Serevent - Allen & Hanburys), a long-acting β 2 -selective adrenergic agonist for inhalation, has been approved by the US Food and Drug Administration for maintenance treatment of…

Med Lett Drugs Ther. 1994 Apr 29; 36(921):37-8
Salmeterol xinafoate ( Serevent - Allen & Hanburys), a long-acting β 2 -selective adrenergic agonist for inhalation, has been approved by the US Food and Drug Administration for maintenance treatment of asthma, with or without concurrent use of inhaled corticosteroids. Salmeterol is not recommended for acute treatment of bronchospasm.
Issue 920 · April 15, 1994
Ophthalmic Levocabastine for Allergic Conjunctivitis

A 0.05% ophthalmic solution of levocabastine hydrochloride ( Livostin - Iolab), a histamine H 1 -receptor antagonist, has been approved by the US Food and Drug Administration for treatment of seasonal allergic…

Med Lett Drugs Ther. 1994 Apr 15; 36(920):35-6
A 0.05% ophthalmic solution of levocabastine hydrochloride ( Livostin - Iolab), a histamine H 1 -receptor antagonist, has been approved by the US Food and Drug Administration for treatment of seasonal allergic conjunctivitis. The new drug is a cyclohexylpiperidine derivative with no structural relationship to any other antihistamine.
Issue 908 · October 29, 1993
Drugs for Tuberculosis

The rising incidence of tuberculosis (TB) has been accompanied by a dramatic increase in drug resistance in some areas of the USA (TR Frieden et al, N Engl J Med, 328:521, 1993). Since poor compliance is the…

Med Lett Drugs Ther. 1993 Oct 29; 35(908):99-102
The rising incidence of tuberculosis (TB) has been accompanied by a dramatic increase in drug resistance in some areas of the USA (TR Frieden et al, N Engl J Med, 328:521, 1993). Since poor compliance is the most important cause of treatment failure and associated with emergence of drug resistance, some experts now recommend that patients with TB take their drugs under direct obeservation (MD Iseman et al, N Engl J Med, 329:576, 1993).
Issue 905 · September 17, 1993
Ketorolac for Seasonal Allergic Conjunctivitis

Ketorolac (kee' toe role ak) tromethamine 0.5%, a nonsteroidal anti-inflammatory drug (NSAID) previously available for parenteral and oral administration ( Toradol - Medical Letter, 32:79, 1990), has now been…

Med Lett Drugs Ther. 1993 Sep 17; 35(905):88-9
Ketorolac (kee' toe role ak) tromethamine 0.5%, a nonsteroidal anti-inflammatory drug (NSAID) previously available for parenteral and oral administration ( Toradol - Medical Letter, 32:79, 1990), has now been approved for ophthalmic use ( Acular - Allergan, Fisons) to relieve itching in seasonal allergic conjunctivitis. NSAIDs decrease prostaglandin concentrations in the eye, which theoretically might contribute to a decrease in itching. Several other NSAIDs are available for ophthalmic use in the USA, but none is marketed for this indication. Flurbiprofen ( Ocufen ) and suprofen ( Profenal ) are promoted for use in ophthalmic surgery to prevent miosis. Diclofenac ( Voltaren ) is available in an ophthalmic solution for treatment of post-operative inflammation after cataract extraction.
Issue 887 · January 8, 1993
Drugs for Pain

Three types of analgesic drugs are available in the USA: first, aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought of as…

Med Lett Drugs Ther. 1993 Jan 8; 35(887):1-6
Three types of analgesic drugs are available in the USA: first, aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought of as analgesics, which act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. (American Pain Society, Principles of analgesic Use , 3rd ed, Skokie, illinois: American pain society, 1992).
Issue 877 · August 21, 1992
Oral Mesalamine for Ulcerative Colitis

An oral formulation of mesalamine (5-aminosalicylic acid, 5-ASA, Asacol - Proctor & Gamble), was recently approved by the US Food and Drug Administration (FDA) for treatment of mildly to moderately active…

Med Lett Drugs Ther. 1992 Aug 21; 34(877):80-1
An oral formulation of mesalamine (5-aminosalicylic acid, 5-ASA, Asacol - Proctor & Gamble), was recently approved by the US Food and Drug Administration (FDA) for treatment of mildly to moderately active ulcerative colitis; it has not been approved for maintenance of remissions. Olsalazine ( Dipentum ), a similar drug (Medical Letter, 32:105, 1990), is approved for maintenance of remissions but not for treatment.
Issue 859 · December 13, 1991
Intranasal Triamcinolone For Allergic Rhinitis

An intranasal formulation of the corticosteroid triamcinolone ( Nasacort - Rh ne- Poulenc Rorer) was recently approved by the US Food and Drug Administration for once-daily treatment of seasonal and perennial…

Med Lett Drugs Ther. 1991 Dec 13; 33(859):116-7
An intranasal formulation of the corticosteroid triamcinolone ( Nasacort - Rh ne- Poulenc Rorer) was recently approved by the US Food and Drug Administration for once-daily treatment of seasonal and perennial allergic rhinitis.
Issue 857 · November 15, 1991
Topical Corticosteroids

Two new topical corticosteroids - fluticasone ( Cutivate - Glaxo), a mediumpotency product, and halobetasol propionate ( Ultravate - Westwood-Squibb), a superhigh- potency drug- were recently approved for…

Med Lett Drugs Ther. 1991 Nov 15; 33(857):108-10
Two new topical corticosteroids - fluticasone ( Cutivate - Glaxo), a mediumpotency product, and halobetasol propionate ( Ultravate - Westwood-Squibb), a superhigh- potency drug- were recently approved for marketing by the US Food and Drug Administration.
Issue 855 · October 18, 1991
Drugs For AIDS And Associated Infections

A growing number of clinical trials now permits some consensus on the treatment of human immunodeficiency virus (HIV) and other infections associated with acquired immune deficiency syndrome (AIDS) in adults.

Med Lett Drugs Ther. 1991 Oct 18; 33(855):95-102
A growing number of clinical trials now permits some consensus on the treatment of human immunodeficiency virus (HIV) and other infections associated with acquired immune deficiency syndrome (AIDS) in adults.
Issue 847 · June 28, 1991
Ondansentron To Prevent Vomiting After Cancer Chemotherapy

Ondansetron (on dan' se tron; Zofran - Glaxo), a serotonin (5-hydroxytryptamine) antagonist, was recently marketed in the USA for intravenous use to prevent nausea and vomiting due to cancer chemotherapy. An…

Med Lett Drugs Ther. 1991 Jun 28; 33(847):63-4
Ondansetron (on dan' se tron; Zofran - Glaxo), a serotonin (5-hydroxytryptamine) antagonist, was recently marketed in the USA for intravenous use to prevent nausea and vomiting due to cancer chemotherapy. An oral formulation is available in many other countries.
Issue 831 · November 16, 1990
Olsalazine

Olsalazine sodium ( Dipentum - Pharmacia), a dimer (two molecules linked by an azo bond) of 5-aminosalicylic acid, was recently approved by the US Food and Drug Administration for oral use to maintain…

Med Lett Drugs Ther. 1990 Nov 16; 32(831):105-6
Olsalazine sodium ( Dipentum - Pharmacia), a dimer (two molecules linked by an azo bond) of 5-aminosalicylic acid, was recently approved by the US Food and Drug Administration for oral use to maintain remission of ulcerative colitis in adult patients who cannot tolerate sulfasalazine ( Azulfidine ; and others).
Issue 820 · June 15, 1990
Drugs for Treatment of Fungal Infections
Med Lett Drugs Ther. 1990 Jun 15; 32(820):58-60
Issue 784 · January 27, 1989
Dexamethasone Bacterial Meningitis In Children

A recent report in the New England Journal of Medicine suggested that in children with bacterial meningitis, adding the corticosteroid dexamethasone ( Decadron ; and others) to antibiotic treatment could…

Med Lett Drugs Ther. 1989 Jan 27; 31(784):6-7
A recent report in the New England Journal of Medicine suggested that in children with bacterial meningitis, adding the corticosteroid dexamethasone ( Decadron ; and others) to antibiotic treatment could decrease the incidence of moderate or severe hearing loss.
Issue 766 · May 20, 1988
Mesalamine For Ulcerative Colitis

Mesalamine ( Rowasa - Reid-Rowell), probably better known as 5-aminosalicylic acid (5-ASA) and also called mesalazine in some other countries, was recently marketed in the USA as an enema for treatment of mild…

Med Lett Drugs Ther. 1988 May 20; 30(766):53-4
Mesalamine ( Rowasa - Reid-Rowell), probably better known as 5-aminosalicylic acid (5-ASA) and also called mesalazine in some other countries, was recently marketed in the USA as an enema for treatment of mild to moderate distal ulcerative colitis, including ulcerative proctosigmoiditis and ulcerative proctitis.
Issue 765 · May 6, 1988
Generic Topical Corticosteroids

Since the last Medical Letter review of generic drugs (Volume 28, page 1, 1986), the prediction that generic drugs newly approved in the USA under more relaxed federal regulations will probably be as reliable…

Med Lett Drugs Ther. 1988 May 6; 30(765):49-50
Since the last Medical Letter review of generic drugs (Volume 28, page 1, 1986), the prediction that generic drugs newly approved in the USA under more relaxed federal regulations will probably be as reliable as brand-name drugs has generally been accurate. Few well-documented generic product failures have been reported. Recently, however, the equivalence of generic topical corticosteroids has been questioned.
Issue 761 · March 11, 1988
Drugs For Treatment of Deep Fungal Infections

The incidence of opportunistic deep fungal infections continues to increase, particularly among patients who have AIDS, are taking immunosuppressive drugs, or are in intensive care units.

Med Lett Drugs Ther. 1988 Mar 11; 30(761):30-2
The incidence of opportunistic deep fungal infections continues to increase, particularly among patients who have AIDS, are taking immunosuppressive drugs, or are in intensive care units.
Issue 756 · January 1, 1988
Nabilone And Other Antiemetic For Cancer Patients

Nabilone ( Cesamet - Lilly), a synthetic cannabinoid chemically related to tetrahydrocannabinol (THC), the main active ingredient in marijuana, was recently marketed in the USA for oral treatment of nausea and…

Med Lett Drugs Ther. 1988 Jan 1; 30(756):2-4
Nabilone ( Cesamet - Lilly), a synthetic cannabinoid chemically related to tetrahydrocannabinol (THC), the main active ingredient in marijuana, was recently marketed in the USA for oral treatment of nausea and vomiting associated with cancer chemotherapy. Oral THC itself, known generically as dronabinol ( Marinol ), is also commercially available as an antiemetic for cancer patients (Medical Letter, 27:97, 1985). Other drugs used for this purpose include metoclopramide ( Reglan - Medical Letter, 24:67, 1982), prochlorperazine ( Compazine ; and others), haloperidol ( Haldol ; and others), and corticosteroids. Benzodiazepines, such as lorazepam ( Ativan ; and others), are used to treat anticipatory nausea and vomiting that occurs before chemotherapy begins.